How often should a healthy person have a body check? Screening intervals the government has published, and why the packages have none, 2026

TL;DR

• The words "body check" cover two things of quite different natures in the marketplace: a screening aimed at one disease, with a defined target group and a defined interval, and a bundle of items sold together as a package. The first has its interval set by an expert committee; the second has its contents set by the seller.
• If you have symptoms, none of the timetables below applies to you. The guidance published by the UK National Screening Committee on 21 November 2023, immediately after the sentence that screening does not provide a diagnosis, says: screening is not for people with symptoms, who should always see their GP [Note 1]. The Centre for Health Protection of the Department of Health's Cancer Prevention and Screening leaflet (self-dated 「二零二五年三月」) likewise says that anyone with symptoms or bodily changes suggestive of cancer should see a doctor as soon as possible for proper diagnosis and treatment. Every interval below applies only to people without symptoms.
• The point most often got wrong: the Hong Kong government does publish a table of what to have at what age and how often — but it is item by item, arranged by age and sex, not an interval for "a whole-body check". The Live Well Plan charts for men and for women from the Primary Healthcare Commission under the Health Bureau (both charts self-noted at the foot "Health Bureau (01/2026)") lay out, on a single page, the age groups and intervals for blood pressure, blood glucose, blood lipids, colorectal cancer, cervical cancer, breast cancer, osteoporosis, vaccination, body weight and oral health. The core reference overview document to which they belong states that this chart is a patient education tool for the general asymptomatic (low-risk) population.
• The intervals on that chart (all of them for average-risk, asymptomatic people only): blood pressure at least once every two years from 18; blood glucose and blood lipids at least once every three years from the 45 to 49 band onwards, and more frequently where risk factors are present; colorectal cancer from 50 to 75, a faecal occult blood test every one to two years, or sigmoidoscopy every five years, or colonoscopy every ten years; cervical cancer from 25 to 64 for women who have ever had sex, every three or every five years, stopping at 65 or above if routine screening over the past ten years has been normal, but those never screened should be screened; breast cancer from 44 to 69, first using the official online risk assessment tool, with those assessed as at increased risk considering mammography every two years.
• What genuinely has no interval is "a package" as a commodity. Among the Hong Kong official documents listed one by one in this article, not one has ever set an interval for "testing a great many things at one go", and not one says how to choose a package, how to read an item count, or how to compare prices.
• The Consumer Council's survey of body check plans published on 15 May 2023 (33 plans) recorded fees from $820 to $8,310, a spread of more than 9 times; among the private healthcare providers, more than 9 in ten (15 plans) offered fewer than half of the basic examination items, and 8 of those offered only 1 assessment item. The same survey also recorded a plan counting "liver function" as 13 separate items. An item count is not a comparable unit.
• The same experts also state in terms which examinations they do not recommend for average-risk asymptomatic people, including lung cancer screening (chest X-ray and low-dose computed tomography included), liver cancer screening (ultrasound and alpha-fetoprotein included), thyroid cancer, ovarian cancer, pancreatic cancer (CA19.9 included) and gastric cancer (gastroscopy and Helicobacter pylori serology included). ⚠️ But all of that is the "average risk" column only. The original has a "higher risk" column for every one of those cancers, and its content can be the exact opposite — people with chronic hepatitis B, hepatitis C or cirrhosis, for instance, are told by the same document to discuss with a doctor having ultrasound and alpha-fetoprotein testing every 6 months.
• The conclusion of the Cochrane update of 2019 (17 randomised trials included, of which the 15 with outcome data covered 251,891 people) is one English sentence: "General health checks are unlikely to be beneficial." ⚠️ It is about the practice of testing a great many things at one go, not about the screenings above with their defined target groups and defined intervals. ⚠️ And the authors themselves offer an explanation in the same passage: one possible reason the effect appears absent is that primary care doctors already identify and act on high-risk patients when they attend for other reasons — which is to say that what cannot be measured is the added increment, not that prevention does not work.
• This article will not tell you which package to buy, which items to have, or how often. Those are individual medical decisions, for a doctor to make against your age, history and risk. Nor will it rank or select any provider, or offer cross-provider price comparisons for packages.

#What is a "body check"? Why do two things have to be separated first?

"Screening" looks for early disease in people without symptoms, aimed at one named disease; a "body check package" is a bundle of items sold together as a commodity. The advertisements give both the same name, but the people who decide their contents and their intervals are entirely different.

Three words first, used with the same definitions throughout:

• Screening: the subjects are people without symptoms, and the purpose is to find disease or a precancerous change before symptoms appear. The Centre for Health Protection of the Department of Health's Cancer Prevention and Screening leaflet (self-dated 「二零二五年三月」) puts it directly: the purpose of cancer screening is to find, before any symptoms have appeared, people who have cancer or a precancerous change, so that treatment can begin early [Note 2].
• Diagnosis: the subjects are people who already have symptoms or an abnormal result, and the purpose is to establish the cause. Screening is not diagnosis, and is not for people with symptoms. The guidance published by the UK National Screening Committee on 21 November 2023 writes two sentences together: screening tests are not wholly accurate and do not provide a diagnosis; screening is not for people with symptoms, who should always see their GP [Note 1]. So every interval below applies only to people without symptoms; the path for someone with symptoms is not a timetable but a doctor.
• General health check or body check package: to define its scope, the Cochrane systematic review of 2019 gave a very serviceable definition: this review defined a health check as screening for more than one disease or risk factor, across more than one organ system [Note 3]. In other words, a package of blood tests plus ultrasound plus an electrocardiogram plus tumour markers is precisely the thing that research is about.

Once those two are separated, a structural difference emerges:

The World Health Organization Regional Office for Europe's screening guide of 2020 was written about exactly this practice of bundling. ⚠️ It sets not one condition but three, to be read together [Note 4]: where more than one test is offered as a combination or as a health check, then before it can be an effective screening programme — each test must meet the same rigorous criteria (those used in deciding whether a screening programme should be started at all); each test must be part of a care pathway; and the way each test is offered must satisfy the requirements set out in the green cells of table 1 of that document.

The same document also writes: carrying out several screening tests at once can lower costs or simplify the process, but each test must be assessed separately on its own merits [Note 4].

In one sentence: bundling can save money, but it cannot dispense with two things — item-by-item validation, and a care pathway behind each item. The second is the one most easily lost inside a package: whether anyone follows up after the test, and how far, is a different matter from how many items were tested.

⚠️ If you are holding a body check package leaflet and want to know how often is right: the question has an answer, but the answer is not a number — it is "it depends which item you are asking about".

#Where did the habit of "a check-up every year" come from?

"An annual physical examination" is a policy proposed in 1922 and withdrawn by its own proposer in 1983; what the proposer recommended putting back in its place was a set of age-specific measures whose contents were to be scrutinised, and which are usually offered in the course of an attendance for some other reason — that is, an item-by-item assessment, not another commodity for you to book yourself.

Dickinson JA and Chee S of the Department of Community and Family Medicine at the Chinese University of Hong Kong set this history down in the December 2000 issue of the Hong Kong Medical Journal (2000;6:415-22) [Note 5]: the concept of the annual physical examination was first proposed by the American Medical Association in 1922; recent doubts about the value of such activity brought evidence-based assessment, first carried out systematically by the Canadian Task Force on the Periodic Health Examination. Those task forces pointed out that performing the same set of interventions on all patients every year is not an effective practice, and therefore recommended abandoning the "annual check-up"; the American Medical Association withdrew its support for that policy in 1983. In its place they recommended that a series of age-specific "health protection packages" be offered, usually in the course of a patient's attendance for some other reason, with the contents of those packages rigorously scrutinised and shown to be of value.

⚠️ That last sentence cannot be cut, because it changes the shape of the answer. When the task forces took away the "annual check-up", they did not put nothing back: what they put back was a set of measures that are age-specific, whose contents are to be scrutinised, and that are done in passing when you attend for something else. Which is to say that what they recommended is not a commodity for you to book at all — and that is also the shape of the Live Well Plan chart discussed below.

The same study reviewed the body check plans of eleven of the twelve private hospitals then in Hong Kong and scored them against the criteria of the Canadian and United States task forces. Every figure below is a figure of December 2000 [Note 5]: the basic packages offered on average 16 tests at HK$2,670; the advanced packages on average 26 tests at HK$6,244. And table 2 shows that about a third of the tests in the basic packages had proven benefit, 17% were of uncertain benefit and about 13% were possibly harmful; about a third were ungraded by either task force, which the authors surmise was mainly because there was insufficient reason to include them in preventive services.

⚠️ "Ungraded" is not "neutral". The original explains in the same sentence why they were ungraded, and the direction is "insufficient reason to include", not "nobody has studied them so it is unknown". The same study also states that its own scoring was deliberately lenient: in this study the authors were deliberately lenient and took an optimistic view of potential benefits, and many experts would be more pessimistic [Note 5]. Both of those sentences are about that set of packages in December 2000, not about today's market.

How the authors themselves described the market of the time: the organisations offering these services appear to believe that more is better; the wide promotion of these packages may give the public the mistaken impression that these are effective preventive services, and that better preventive care means being willing to spend more [Note 5].

⚠️ There is a sentence in that study which no longer applies, and it has to be given together with what followed. It wrote that no authoritative body in Hong Kong issues formal guidelines. That was true in December 2000 and is no longer true today. On cancer, the Cancer Expert Working Group on Cancer Prevention and Screening under the Cancer Coordinating Committee (the expert working group) now publishes recommendations of exactly that kind; on the three highs there is the Chronic Disease Co-Care Scheme; and on the wider question of which preventive items belong to which age, the Primary Healthcare Commission under the Health Bureau has published the Live Well Plan charts (below). What remains unfilled today is not "general preventive care" but "the commercial body check package as a commodity" — no official document says what a package should contain, how often to buy one, how to compare them, or how to read the item count on a leaflet.

⚠️ If you take "one check a year" for common sense: that common sense has a source, and its proposer has withdrawn it — and said, on withdrawing it, what was to go back in its place: a set of age-specific measures, contents scrutinised, usually done while you are attending for some other reason.

#Why is "testing more items" not "testing better"?

Because every test added adds a chance of being wrong at the same time; and in a group of people who do not have the disease, those chances accumulate faster than most people imagine.

This mechanism is the backbone of the whole article, and three concepts have to be kept apart first (the definitions below are from the WHO Regional Office for Europe's screening guide of 2020):

• Sensitivity: a test's ability to identify a person who has the disease as positive.
• Specificity: a test's ability to identify a healthy person as negative.
• Positive predictive value: where the test result is positive, the likelihood that the person tested really does have the disease.

The third is the one the reader actually holds, and it has a counter-intuitive property. The same WHO document writes [Note 6]: a test's positive and negative predictive values both depend on the prevalence of the disease in the population being tested, so the same screening test gives different results in different populations; and where a disease is rarer in a place (low prevalence), the positive predictive value is lower — so that even with the same sensitivity and specificity, there will be more false positives than in a high-prevalence place.

Which is to say: the same machine, the same reagent and the same technologist, applied to a group of healthy people, will be wrong a greater share of the time than when applied to a group of patients with symptoms. That is not a question of machine quality; it is arithmetic.

The Hong Kong Consumer Council's press release of 14 July 2016, issued after seeking the views of the Department of Health, the Hong Kong College of Pathologists and the Hong Kong Medical Association, described the packages on the market by the same reasoning (the page is self-dated 2016.07.14) [Note 7]: the report cites expert opinion that the health check packages commonly on the market are largely of the "unconditional" kind, that is, not determined by medical judgment and clinical need but a catch-all of examinations and tests on people without symptoms in the hope of finding hidden disease early, and that the approach may not work.

The same press release went through two items common in Hong Kong packages [Note 7]: using a resting or exercise electrocardiogram to detect coronary artery disease produces a high rate of false positive results in people with a low incidence of disease and no symptoms whatever; and using a chest X-ray as a tool for lung cancer screening has insufficient sensitivity, with a higher chance of false negative results. And on tumour markers: no "tumour marker" test at present has sufficient sensitivity and specificity to be used alone as a cancer screening test.

#Doing the arithmetic once (an example): on a blood report of 20 items, what are the chances that everything is normal?

"Pitfalls in interpreting laboratory results", published in Australian Prescriber on 1 April 2009, explains how laboratories set a "normal range": by convention, the reference range a laboratory reports covers 95% of the reference population [Note 8].

Then comes its own subheading and calculation [Note 8]: one machine can run a multiple biochemical analysis at one go, producing 20 results; assuming those results are independent of one another (which they are not) and that the results in the reference population are normally distributed (which they may not be), then only 36% of normal people will have all 20 results inside the reference range, and 64% will have at least one abnormal result.

Following the arithmetic: 0.95 × 0.95 = 0.9025, so about 90% for both of two items; 0.95 raised to the power 20 = 0.3585, that is about 36%; leaving 1 − 0.3585 = 0.6415, about 64%. That 64% is not a proportion of patients; it is the proportion, among people who are in fact healthy, who will have at least one value out of range.

⚠️ Four limits have to be given with it, and all four are the original's own. First, the original itself writes "which they are not" and "which they may not be" — it knows both assumptions do not hold completely. Second, the "item count" advertised for a package is not the number of independent tests (there is an example below of one thing counted as 13), so this calculation cannot be applied directly to a package badged "102 items". It demonstrates a direction, not a coefficient to be carried anywhere. Third, the original has a sentence immediately following in the same passage that points the other way: the more extreme a value is, and the more related items are abnormal at once, the greater the chance that the abnormality has clinical meaning [Note 8]. The same article also calculates that with a 99% and a 99.9% reference range instead, the proportions with all 20 items inside the range are 82% and 98% respectively. Which is to say that the 64% is about whether anything falls out of range, not by how much — a value barely over the line and a value far off mean entirely different things, and telling them apart is the doctor's work. Fourth, the premise of a "95% reference range" does not itself hold for every item, as the original also says [Note 8]: some items vary so much across the population that the reference range a laboratory reports may cover only a smaller part of it — the commonly used reference range for serum insulin, for instance, may cover only one standard deviation either side of the mean, that is 68% of the reference population; in which case, by the reported reference range, 16% of normal people will have "high insulin" and 16% "low insulin", so serum insulin is not a useful test for assessing "insulin resistance".

So the words "out of range" stand for quite different degrees of rarity on different items — on the original's own example of serum insulin, by that 68% range, "high" and "low" together account for 16% + 16% among healthy people, that is roughly one healthy person in every three flagged as out of range. To know which range applies to a given item on your own report, look at the range printed on it, or ask a doctor. (How reference ranges come to be set, and how the numbers on a laboratory report should be read, is the subject of another article — see our piece on laboratory and imaging reports.)

As for the idea that more is better, there are sellers in Hong Kong who do not agree with it themselves. Quality HealthCare writes in the frequently asked questions on its health check page: 「很多人以為驗身套餐中的體檢項目越多越好，其實這想法是不正確的…或會浪費金錢和時間。」 — many people think that the more items in a body check package the better, but that idea is not correct, and it may waste money and time (retrieved 2 August 2026).

⚠️ If you are holding a report with an asterisk or two and imagining the worst: in a group of healthy people, having at least one out-of-range value is the norm rather than the exception — but that sentence does not mean you can decide for yourself that your asterisk does not matter; the reading of it is for a doctor.

#Does a general health check actually do anything? Has anyone measured it directly?

Yes, and with randomised controlled trials; the conclusion is that no difference can be seen in all-cause mortality, cancer mortality or cardiovascular mortality.

• The study: Krogsbøll LT, Jørgensen KJ, Gøtzsche PC, General health checks in adults for reducing morbidity and mortality from disease, Cochrane Database of Systematic Reviews 2019, issue 1, Art. No.: CD009009 (DOI 10.1002/14651858.CD009009.pub3). cochrane.org's own record page prints "Published 30 January 2019".
• Included: 17 randomised trials, of which 15 had outcome data, covering 251,891 participants in all.
• Literature search cut-off: 31 January 2018. That is the currency of this body of evidence.

The main results, with both arms and the certainty grades [Note 9]: health checks have little or no effect on all-cause mortality (risk ratio 1.00, 95% confidence interval 0.97 to 1.03; 11 trials; 233,298 participants, 21,535 deaths; high-certainty evidence), and likewise on cancer mortality (risk ratio 1.01, 95% CI 0.92 to 1.12; 8 trials; 139,290 participants, 3,663 deaths; high-certainty evidence), and probably little or no effect on cardiovascular mortality (risk ratio 1.05, 95% CI 0.94 to 1.16; 9 trials; 170,227 participants, 6,237 deaths; moderate-certainty evidence). The authors' conclusion in one sentence: general health checks are unlikely to be beneficial.

In other words: a risk ratio of 1.00 means the mortality of the two groups, checked and not checked, is the same; and a confidence interval of 0.97 to 1.03 is narrow, which means "no difference could be measured" rather than "the measurement was not precise enough".

⚠️ But "no difference could be measured" is not "screening does not work" — that is the review authors' own point in the same passage, and it must be given with the result. In the plain language summary, immediately after the results, they offer two possible explanations, the first being: one reason the effect appears absent may be that primary care doctors have already identified patients as high risk and intervened when they attended for other reasons [Note 9]. The second explanation is the "may not attend" sentence in the table below.

Neither explanation points at "health checks are harmful" or "prevention does not work", but at the added increment of this particular product being unmeasurable — because a family doctor is already doing the same thing in the course of ordinary consultations. What that means for a reader in practice: the starting point for prevention is a doctor who knows your history, not one more package bought.

⚠️ This article quotes the English original because Cochrane's own published traditional-Chinese translation diverges from the English in two sentences, and this article takes the view that a reader should know. The two divergences:

The English says "unlikely to be beneficial"; the Chinese translation says "may not be the most cost-effective" — a far weaker statement. The English says that high-risk people "may not attend"; the Chinese translation says they "may agree to attend" — the exact opposite meaning. The review was written in English, and the Chinese page itself is marked as a translation and names its translators, so this article takes the English original as authoritative and sets out the difference.

Three things that cannot be inferred from this review (all of them the original's own limits):

1. What it included was adults not selected by disease or risk factor. People who already have symptoms, or who fall into a defined high-risk group, are outside the scope of this conclusion.
2. "We did not include geriatric trials." So it has said nothing about checks designed for older people.
3. What it compared was being invited to a health check or not, not which package is better.

⚠️ If you feel that having a check must be better than not having one: that intuition is not supported by data on 250,000 people — but the same study has not said that targeted screening does not work; what it is about is the practice of testing a great many things at one go; and the authors themselves propose, as one possible reason no difference could be measured, that family doctors are already identifying and intervening in the course of ordinary consultations.

#Which diseases and which people has officialdom actually set screening for?

What the expert working group publishes is not only a list of what is recommended but an equally long list of what is not; and the second is the more useful of the two to a reader holding a package leaflet.

Everything below is from the Centre for Health Protection of the Department of Health's Summary of Cancer Screening Recommendations of the Cancer Expert Working Group on Cancer Prevention and Screening (Chinese version PDF, the document self-noted 「衞生署 衞生防護中心 2026 年」, retrieved 2 August 2026). The year in brackets is the year the recommendation itself carries.

#Table one: screenings not recommended for average-risk, asymptomatic people

⚠️ The original summary table has two columns, and the table above is one of them. The original divides every cancer into an "average risk" and a "higher risk" column of asymptomatic people, and everything above comes from the "average risk" column. If you have a family history, carry a relevant genetic mutation, or have chronic hepatitis B or C or cirrhosis, you are outside the scope of the table above, and the other column of the same document has different, sometimes opposite, recommendations for you. The example most directly relevant to body check packages is item 5 of the liver cancer section: people with chronic hepatitis B, hepatitis C or cirrhosis of any cause are at higher risk of hepatocellular carcinoma; such high-risk people should seek a doctor's advice about having ultrasound and alpha-fetoprotein testing regularly every 6 months [Note 10]. The higher-risk column of the lung cancer section also has a sentence pointing the other way: 「不建議較高風險的無症狀人士接受以胸肺X 光檢查或痰液細胞檢查方式進行肺癌篩查。」

⚠️ But the "higher risk" column does not uniformly tell you to go and be tested — the pancreatic cancer column runs the other way and cannot be generalised with the rest. Item 2 of the original on pancreatic cancer: given the insufficiency of the available evidence, uniform pancreatic cancer screening is not recommended for higher-risk people; and those at greatly increased risk of pancreatic cancer because of a strong family history, a specific genetic syndrome or certain hereditary predisposition characteristics may consider seeking a doctor's advice for individual assessment [Note 10].

Which is to say: on pancreatic cancer, "I am at higher risk" does not by itself move you from "not recommended" to "recommended". The higher-risk columns of the nasopharyngeal, thyroid, ovarian and gastric cancer sections tell the people concerned to consult a doctor on whether and how screening should be done. The content of that column is for a doctor to judge against your circumstances, and cannot be matched against a table by yourself.

⚠️ There are three different formulations in this table and they cannot be flattened into one. "Not recommended", "insufficient evidence to recommend" and "insufficient scientific evidence to support or oppose" are three different positions. The third means "neither side has been settled", not "do not do it".

⚠️ The item following the prostate cancer row is more than one sentence, and it is the later sentences that are of use when you are holding a package leaflet. The full text of item 3 [Note 10]: an asymptomatic man considering prostate cancer screening should discuss the potential benefits and harms of screening with a clinical healthcare professional so as to make an informed choice; in general, the recommended screening method is the prostate-specific antigen blood test; the ages at which to start and stop screening, and the screening interval, should be decided on individual circumstances; digital rectal examination should not be used as the sole method of prostate cancer screening.

Which is to say: within the position of "insufficient evidence to support or oppose", the expert working group has still spoken on which method — if it is done, the method is the prostate-specific antigen blood test; and digital rectal examination on its own is not suitable as prostate cancer screening. As for the age to start, the age to stop and how often, the original states in terms that it depends on individual circumstances — which is to say that this table has never set an interval for prostate cancer at all.

The last page of the same summary table carries a general note: 「重要注意事項：接受癌症篩查前應與你的醫療服務提供者討論相關的好處和風險。」 — before having cancer screening, discuss the benefits and risks with your healthcare provider.

#Table two: the three that are recommended, with their target groups and intervals

⚠️ The asterisk on the breast cancer row is the original's own footnote and cannot be cut. The original reads: 「*包括有直系親屬曾患乳癌、曾診斷患有良性乳腺疾病、從未生育或第一次生產年齡晚、初經年齡早、體重指數偏高和缺乏體能活動」 — a first-degree relative with breast cancer, a previous diagnosis of benign breast disease, nulliparity or a late age at first birth, an early age at menarche, a raised body mass index, and physical inactivity. Without that sentence, "certain combinations of personalised breast cancer risk factors" in the table above is something a reader cannot look up. The full account of breast cancer screening — including how that online risk assessment tool is used — is in our article on breast cancer screening.

⚠️ Of the three items in table two, colorectal and cervical cancer each have a "higher risk" column of their own in the original, and their starting ages are much earlier than the table above; breast cancer cannot be described that way. The breast cancer passage extracted below is marked in the original as "moderate risk" (not "higher risk"), and its text only says every two years, with no starting age mentioned at all. All three passages below are from the original of the same summary table, and are reproduced in full at [Note 11]:

Colorectal cancer (items 2 to 4 of the higher-risk column): people carrying a Lynch syndrome gene mutation, from 25, colonoscopy every one to two years; people carrying a familial adenomatous polyposis gene mutation, from 12, sigmoidoscopy every two years; and people with one first-degree relative diagnosed with colorectal cancer at or before 60, or two or more first-degree relatives with colorectal cancer (at whatever age of diagnosis) but without hereditary bowel disease, from 40 or from ten years before the age at diagnosis of the youngest affected relative (but not before 12), colonoscopy every five years.

Cervical cancer (items 6 to 7 of the higher-risk column): women aged 21 to 24 who have ever had sex and who have risk factors for infection or persistent infection with HPV or for cervical cancer are regarded as higher risk and should be screened according to a doctor's assessment and advice; other higher-risk women must be assessed by a doctor and may need more frequent screening.

Breast cancer (moderate risk) (item 6 of that column): women at moderate risk of breast cancer (that is, with one first-degree female relative diagnosed with breast cancer at or before 50, or two first-degree female relatives diagnosed after 50) are recommended to have mammography screening every two years; magnetic resonance imaging is not recommended for breast cancer screening in women at moderate risk.

In one sentence: a 44-year-old whose father was diagnosed with colorectal cancer at 55 would, reading the "50 to 75" of table two, wait six years too long; the higher-risk column of the same document tells them colonoscopy every five years from 40. That column is for a doctor to judge against your family history and genetic status, and is not something to be matched against a table yourself.

⚠️ This article does not reproduce the rule on the age to begin screening for the high-risk breast cancer group (a confirmed pathogenic BRCA1 or BRCA2 mutation, for instance). The Chinese and English versions of that rule differ on the definition of "the youngest affected relative", and it is in any case a rule that needs clinical assessment before it can be used; see our article on breast cancer screening.

⚠️ There is an easily triggered trap on colorectal cancer. Table two is a clinical recommendation with three options. The government-funded Colorectal Cancer Screening Programme uses one of those arrangements (a faecal immunochemical test arranged through a participating primary care doctor), and that is an operating rule of the programme, not the clinical recommendation itself. The two cannot stand in for each other. The full accounts of cervical cancer, colorectal cancer and endoscopy are in our three articles on cervical cancer screening, colorectal cancer screening, and colonoscopy and gastroscopy; this article does not repeat them.

⚠️ The summary table is bilingual, but the complete professional recommendation documents are in English only. The Chinese interface of the Centre for Health Protection's expert working group page marks each of the eleven professional recommendations 「(只備英文版)」 — English version only. So all the Chinese quoted in this article comes from the bilingual summary table, not from the full professional recommendations.

#What shape does the screening the government pays for itself take?

The Hong Kong government does have schemes subsidising screening for asymptomatic adults, and their design is itself an answer. The Primary Healthcare Commission's official page now describes two together: the Chronic Disease Co-Care Scheme (regularised from the pilot and renamed on 13 March 2026) and the Hepatitis B Co-Care Scheme.

The eligibility criteria are set out on the official "Eligibility" page under two headings, reproduced in full at [Note 12]. The Chronic Disease Co-Care Scheme: a Hong Kong resident aged 45 or above; and not already diagnosed with diabetes mellitus or hypertension. The Hepatitis B Co-Care Scheme: a Hong Kong resident born in or before 1988 (the year the universal neonatal hepatitis B vaccination programme was introduced); and with a family member (parent, sibling or child) or a sexual partner who is a chronic hepatitis B carrier; and not already diagnosed with chronic hepatitis B and without related symptoms; and never having completed the full course of hepatitis B vaccination.

What does the screening stage cover? The official page reads: assessment and arrangement of screening tests by a family doctor / referral by the family doctor to a designated medical laboratory for a blood sample / explanation of the laboratory report and the diagnosis by the family doctor, with a suitable health management plan arranged / a free hepatitis B surface antigen rapid test arranged by a District Health Centre (for the Hepatitis B Co-Care Scheme only) [Note 12]. The scope of the chronic disease scheme is diabetes mellitus and hypertension, with blood lipid testing added from 28 March 2025, making up the "three highs".

That is a contrast: when the Hong Kong government decides to pay for screening asymptomatic adults, what it buys is a named risk factor, an age floor or a family contact condition, an exclusion, and a family doctor with a treatment pathway behind them — not a list of items. The shapes differ: one side has a defined target group, exclusions and a follow-up; the other is a set of values bought at one go.

⚠️ But it has to be said in the same breath: the $120 is the price of the testing step, not the price of the road that follows a finding. The "Subsidy and Co-payment" page of the same site splits the co-payment into a "screening stage" and a "treatment stage", all of it in the original:

In one sentence: the $120 is the price of the testing step, not the price of the road that follows a finding. Below, this article cites the UK National Screening Committee telling consumers to ask a private provider whether following up a result costs extra — the same question has to be asked of a government scheme, and for the government scheme the answer is printed in public.

Elderly Health Care Vouchers can be used on a body check, but two things have to be kept apart. Item 7 of the "Services covered" section of the voucher scheme's frequently asked questions asks whether vouchers may be used for minor surgery in a private clinic, and the answer states the scope of the vouchers in passing: vouchers may be used for preventive and curative services, but not for the purchase of goods alone, such as drugs, spectacles, dried seafood, personal care products, food or medical supplies [Note 13].

⚠️ The place on the same page that says it most plainly, printing the words for "body check" in terms, is about the reward and not about the vouchers. Item 41 of that page asks what restrictions apply to the reward under the Elderly Health Care Voucher Reward Pilot Scheme, and answers: the reward may be used only for specified primary healthcare purposes such as disease prevention and health management, including western medicine health assessment, body checks, screening, immunisation, prescribing preventive drugs and managing chronic disease [Note 13]. That sentence is about the restrictions on the reward, not a list of the service scope of the vouchers themselves; that page has no separate list of "the scope of western medicine services". The reward is a pilot scheme running from 2024 to 2026, and item 39 of the same page states: an eligible older person who uses a cumulative 1,000 dollars or more of vouchers in the same year on specified primary healthcare purposes such as disease prevention and health management will automatically be granted a 500-dollar reward into their voucher account for the same purposes, usable until the end of the following calendar year and void thereafter [Note 13].

⚠️ "The voucher scheme covers preventive services" and "a given body check centre will take your voucher" are two different things. Whether a particular provider accepts them, and on what additional conditions (a referral letter, or a previous attendance, for instance), is something this article makes no statement about for any provider — ask the provider directly before buying.

⚠️ If you see "thyroid ultrasound", "tumour markers" or "chest X-ray" in a package and do not know how to weigh them: table one is not saying those examinations are useless; it is saying that for average-risk people without symptoms, Hong Kong's expert working group does not recommend them as screening. And whether you are average risk is itself for a doctor to judge.

#So how often, then?

Item by item, the Hong Kong government has a published table laying out the intervals for different items by age and sex; but the question "how often should a package be done" has no answer, because officialdom has never written its recommendations in the unit of a package at all.

#The government has laid out a table of its own: the Live Well Plan

The Primary Healthcare Commission under the Health Bureau has published, under the primary healthcare Reference Framework series, a Hong Kong Reference Framework for Life Course Preventive Care in Primary Healthcare (the core document's cover self-noted "First Edition 2023" and "First published: 2023", 31 pages in all), with three Life Course Preventive Care Plan charts attached: children, men and women. The charts for men and for women both print "Health Bureau (01/2026)" at the foot.

⚠️ Those three charts exist in English only. The Chinese interface of the Health Bureau's reference framework site marks each of the three 「(只備英文版)」, with the Chinese names 「健康人生計劃 - 兒童」, 「健康人生計劃 - 男士」 and 「健康人生計劃 - 女士」. So what is quoted below is the English original.

One chart has four blocks — Immunisation, Healthy Lifestyle, Screening for Chronic Diseases, and Cancer Screening; the horizontal axis is age bands, from a 19-24 band, in five-year bands, with the last band 65 or above.

In prose, the three cancer screening rows of that chart read: colorectal cancer, average risk aged 50 to 75, a faecal occult blood test annually or biennially, or sigmoidoscopy every five years, or colonoscopy every ten years; and cervical cancer, women aged 25 to 64 who have ever had sexual experience should have regular cervical screening — from 25 to 29, cytology every three years after two consecutive normal annual screenings; from 30 to 64, that same option, or human papillomavirus testing every five years, or co-testing every five years; and at 65 or above, screening may be discontinued where routine screenings within ten years have been normal, while a woman who has ever had sexual experience but has never had cervical screening should be screened.

The chart says for itself who it is written for and what it is for. Chapter 5 of the core document [Note 14]: this plan focuses on preventive measures applicable to the general asymptomatic (low-risk) population, and provides additional information on individual risk assessment for higher-risk people in respect of immunisation and cancer screening. The same chapter lists four uses, the last of them "(d) patient education tool" — which is to say that the chart is itself printed for the public to read.

⚠️ But the same chapter also states that it is not a complete list: this plan is not intended to be exhaustive and will be updated regularly in line with the latest evidence [Note 14]. The foot of the chart likewise prints that the plan above is not exhaustive and other preventive care measures may be considered. Not being on this chart does not mean it need not be done.

⚠️ There is a further column on the right of the same chart headed "Individual Risk Assessment", about who should start earlier or go more frequently. The men's chart lists, under high-risk factors for metabolic disease and hypertension [Note 15]: a smoking history; a sedentary lifestyle; overweight or obesity; central obesity (a waist circumference of 90 cm or above); prediabetes; a family history of diabetes or hypertension; and a family history of heart disease. The same column on the women's chart puts the waist threshold at 80 cm or above, and adds a history of polycystic ovary syndrome, a history of gestational diabetes, a history of pre-eclampsia in pregnancy, and having given birth to a baby of 4 kg or more. The heading of the cancer screening column reads that higher-risk people need to start earlier and/or be screened more frequently. The intervals in the table above are the version for people without those factors.

In one sentence: the government's answer is not "how often to have a check-up" but "what age you are and whether you are a man or a woman, and therefore which items you have reached". No cell on that chart says "whole-body check", and no cell says how often a package covering several organ systems should be bought.

⚠️ If you have assumed the government has said nothing: it has, and on a single page — but the units it lays out are the item and the age, not the package. Someone holding a leaflet looking for one overall number will not find it on that chart.

#Blood pressure: the one item cited here that even has a rule for when to test next

The blood pressure row of the chart above says at least once every two years, and the document behind that item goes further, and it has a Chinese version. Chapter 7 of the Chinese version of the Hong Kong Reference Framework for Hypertension Care for Adults in Primary Care Settings (the full Chinese document's cover self-noted 「2021年修訂版」, 「首次出版年份：2010」 and 「最後更新日期：2021」) prints: measure blood pressure at least once every two years in all adults aged 18 or above [Note 16].

But the table on the same page states that when to test next varies with what you measured this time:

⚠️ The original table has five notes, two of which govern that "recommended interval" column directly and change the reading if cut [Note 16]: note 1 — the categories are based on seated office blood pressure, and where the systolic and diastolic levels fall in different categories, the higher category should be used as the classification of the blood pressure level; note 2 — where the systolic and diastolic categories differ, the blood pressure may be rechecked at the shorter interval; note 3 — the interval may be adjusted according to previous blood pressure readings, the presence of other cardiovascular risk factors, or the presence of target organ disease.

In one sentence: when the two numbers are not on the same row, follow the higher row, and the shorter interval may be used. A worked example straight off the table: a systolic of 118 is on the "optimal" row, but a diastolic of 86 is on the "high normal" row — by note 1 the classification follows the higher, that is "high normal"; by note 2 the shorter interval may be used. The "within two years" read off the optimal row alone is not the answer in that case.

Officialdom's answer to "how often should blood pressure be checked" is not a fixed number but a rule that turns at once on the higher of your two readings' categories and on your previous readings and risk factors. Two years, one year and six months are three different answers. That shape is nothing like the shape of "a package once a year" — the latter is the same interval whatever your last result was.

⚠️ The nine professional Modules of this reference framework exist in English only, and even the Chinese pages link to the English files. The Chinese quoted above comes from Chapter 7 of the core document, which does have a Chinese version.

#The same question, answered in two different shapes by the Consumer Council and the government

The Consumer Council (the page self-dated 2023.05.15): the Council writes that a body check is to some extent a bespoke service, because health status and risk differ from person to person, so that there is no rigid set of specified or standard items that must be followed, and it advises consumers to consult a family doctor and have the doctor assess their risk. Immediately after, the same paragraph introduces a set of intervals with 「例如」, for example: an average person should have a hypertension check at least 1 time a year; those aged 45 or above should have blood glucose checked every 3 years to assess diabetes risk; those aged 50 to 75 should have blood lipids checked every 3 years, and a faecal occult blood test 1 time every 1 to 2 years, or a sigmoidoscopy 1 time every 5 years, or a colonoscopy 1 time every 10 years.

The government (Centre for Health Protection press release, 17 May 2026): according to the Hong Kong Reference Framework for Hypertension Care published by the Primary Healthcare Commission, adults aged 18 or above should have their blood pressure measured at least once every two years; individuals may need to monitor their blood pressure more frequently depending on their blood pressure level, age, overall risk of coronary heart disease and their doctor's advice [Note 17].

In one sentence: the Council's sentence is a flat number (at least once a year), and the government's is a conditional rule (at least once every two years, then narrowed by your last reading and your risk factors). The two do not contradict each other — measuring once a year still satisfies "at least once every two years" — but they are two different shapes of advice, and the shape is what a reader actually takes away and uses.

⚠️ Two things to be clear about.

First, the three non-cancer intervals in the Council's passage carry no source on that page, but that does not mean they have none. The passage is introduced with 「例如」 and there is no source line anywhere on the page; as for the colorectal cancer figures in the same passage, they agree exactly with the expert working group's summary table. The intervals for blood pressure, blood glucose and blood lipids, however, are printed in the Health Bureau's own Live Well Plan: blood pressure at least once every two years, and blood glucose and blood lipids at least once every three years. So the real difference is not "sourced against unsourced" but two figures, one official and one not, differing on the same item — the Council writes yearly for blood pressure where the government writes at least once every two years; and the Council writes 50 to 75 for blood lipids where the Live Well Plan band starts at 45 to 49. Taking the more frequent of the two is a safe course, but know which document you are following.

Second, the reference framework cited in that press release of 2026 is, in its current version, self-noted as the 2021 revised edition, first published in 2010. The version year a document notes for itself and whether the recommendation inside it still applies are two different things, and this article states only the first.

#What has no interval is "a package"

Not one of the Hong Kong official documents listed one by one below sets any interval for "buying a body check package covering several organ systems at one go", and not one gives guidance on how to choose a package, how to read an item count, or how to compare prices. That is a negative statement, so its scope has to be set out document by document:

• The Health Bureau Primary Healthcare Commission's Live Well Plan charts for men and for women (foot self-noted "Health Bureau (01/2026)") and the core document to which they belong (First Edition 2023) — arranged throughout by age and item, with no cell that is "a package".
• The full Chinese and English texts of the Centre for Health Protection's Summary of Cancer Screening Recommendations of the Cancer Expert Working Group on Cancer Prevention and Screening (2026) — organised cancer by cancer and risk group by risk group.
• The Chinese and English versions of the Centre for Health Protection's Cancer Prevention and Screening leaflet (「二零二五年三月」).
• The Chinese and English versions of the Centre for Health Protection's "Men's body check — an introduction to men's health checks" page. ⚠️ That page belongs to the Centre for Health Protection's men's health section and has no women's counterpart, so it is material written for men and cannot be taken as the government's answer for everyone. It never gives an interval, and hands the question back to a doctor twice — on what to test: 「醫生會按個別人士的年齡、性別、健康狀況和家庭健康背景等而建議所需要檢查的項目。」 and on when to test again: 「要聽取報告，並要求醫生給予你建議如何跟進問題和下次檢查的時間。」 [Note 18]
• The full Chinese and English texts of the Medical Council of Hong Kong's Code of Professional Conduct for the Guidance of Registered Medical Practitioners (revised October 2022) — nothing anywhere in it governs commercial body check packages. The one provision in the code that touches body checks is about the nature of the relationship rather than the content: section 1.2.1, 「當醫生為任何人士進行健康檢查時，雙方即時建立起醫生與病人的關係，這種關係應該時刻得到尊重。」 — when a doctor conducts a health check on any person, a doctor-patient relationship is immediately established, and that relationship should be respected at all times.
• The Hong Kong Academy of Medicine's published list of policy statements and research reports (8 in all) — all on training, education or diversity and inclusion, none touching clinical screening or preventive care.
• The Hong Kong College of Family Physicians' website, site map, official statements page (listing 7 press releases) and the archive of the Hong Kong Practitioner journal — carrying no college-level general body check guideline.

⚠️ The list above does not include the following two, on which this article makes no statement either: the Hong Kong Medical Association (hkma.org / thkma.org) and the Department of Health's Central Health Education Unit and health education hotline (cheu.gov.hk).

By way of contrast: the UK government does have a "multi-item check" of its own, and its shape is narrow. The NHS Health Check (the page self-dated "Page last reviewed: 14 August 2023") states [Note 19]: it is a free heart and blood vessel health check; it is for people aged 40 to 74 without a pre-existing condition such as heart disease, chronic kidney disease, diabetes or hypertension; and eligible people should be invited by their GP or local council once every five years.

So even a multi-item check provided by a government is: aimed at one system (cardiovascular), with the age range pinned down, excluding those already ill, once every five years. Not annual, and not whole-body.

⚠️ If you plan on "one check a year" and want an official number behind it: item by item there are numbers, and the government has them laid out on one page — but the official intervals for different items run from six months to ten years, with no common answer that can be tied into "a year", and no cell that is about "a package".

#What does "everything is normal" on a report mean?

It means that these particular tests, this time, found no abnormality; it does not mean you have no disease. That distinction has been written down by the Department of Health, the NHS, the United States Food and Drug Administration, and by sellers in Hong Kong themselves.

The Centre for Health Protection of the Department of Health's Cancer Prevention and Screening leaflet (「二零二五年三月」): all screening tests have their limitations and are not wholly accurate [Note 2].

The NHS screening overview page (self-dated "Page last reviewed: 30 July 2024") states [Note 20]: if you get a normal result after screening ("screening negative"), it means you are at low risk of having the condition screened for; that does not mean you will never develop it in future, only that you are at low risk at present; even if your screening result is normal or negative (that is, you are not at high risk), you may still go on to develop the condition.

The UK National Screening Committee's guidance of 21 November 2023 states the consequence of a false negative plainly [Note 1]: false negatives are equally unavoidable in screening — the disease is present or about to appear, but the test result is normal; this gives false reassurance, so that symptoms may later be ignored in the belief that all is well, delaying diagnosis and treatment.

Sellers in Hong Kong have written the same thing themselves. The terms of service of Medtimes (retrieved 2 August 2026): 「所有身體檢查並非作為醫務診斷或治療用途。謹此提醒閣下，儘管檢查結果表面上屬正常，還是有可能有某些隱藏的疾病在稍後時間才會顯現。」 — no body check is for medical diagnosis or treatment, and although results may appear normal, there may be hidden disease that only becomes apparent later.

⚠️ Among the eighteen providers' own published pages listed below (as at 2 August 2026), the sentence "a normal result does not mean no disease" was found on the pages of one only, and printed in the terms of service rather than on a package page. That statement is about those eighteen providers' pages on that day, not about the Hong Kong market.

#What this section will not do

This article will not supply any rule by which you could "rule out" an emergency yourself. It will not list which symptoms do not matter, and will not say that without such-and-such symptoms you need not see a doctor. The reason is simple: a typical presentation is not an exclusion rule. If you have symptoms, see a doctor first — the direction is one-way: a clinician rules out the dangerous possibilities first, and only then does the benign explanation get its turn; and a screening report never overrides a symptom. Tsuen Wan Adventist Hospital's own article puts it the same way: 「倘若感到身體不適或有異常症狀，應先立即求醫，透過醫學評估確認是否需要接受相關的入侵性或放射性檢查，而並非擅自購買一大堆自選體檢服務。」 — if you feel unwell or have unusual symptoms, seek medical attention at once and have a medical assessment establish whether an invasive or radiological examination is needed, rather than buying a great many optional body check services on your own initiative (retrieved 2 August 2026).

By the same reasoning, this article does not reproduce the low-dose computed tomography screening thresholds in the lung cancer section of the expert working group's document (pack-years, years since quitting, and the ages to start and stop). Those figures are indeed printed in an official document, but the same passage also states in terms that they are criteria from overseas literature, and that 「由於目前尚未有充分證據證明此等準則適用於本地情況，因此重度吸煙人士應與醫生商討接受低輻射量電腦掃描篩查的利弊」 — since there is as yet insufficient evidence that those criteria apply locally, heavy smokers should discuss the benefits and harms of low-dose computed tomography screening with a doctor. Printing as a self-check list a set of figures whose local applicability Hong Kong has expressly not established would have readers judging themselves by a standard Hong Kong has not adopted. Someone with a long smoking history should talk to a doctor, not match themselves against a table.

#False positives, and what follows them

A false positive is not over with the fright; it usually brings on the next round of testing. What follows is the intervention-arm data of a randomised controlled trial whose exposure is precisely "a set of tests sold to people without symptoms":

Croswell JM et al., Cumulative incidence of false-positive results in repeated, multimodal cancer screening, Ann Fam Med. 2009 May-Jun;7(3):212-22 (PMID 19433838). The study population: the intervention arm of the PLCO cancer screening trial, 68,436 participants aged 55 to 74; men had chest X-ray, sigmoidoscopy, digital rectal examination and a prostate-specific antigen blood test, and women CA-125, transvaginal ultrasound, chest X-ray and sigmoidoscopy; up to 14 tests each over a three-year screening period.

The results [Note 21]: after 14 tests, the cumulative risk of at least one false positive was 60.4% in men (95% CI 59.8%–61.0%) and 48.8% in women (95% CI 48.1%–49.4%); and the cumulative risk of undergoing an invasive diagnostic procedure because of a false positive was 28.5% in men (95% CI 27.8%–29.3%) and 22.1% in women (95% CI 21.4%–22.7%).

Doing the arithmetic once (an example): the same group rewritten as "per 1,000 people" — all of the following are from the same study, the same participants and the same run of 14 tests, and so can be put side by side:

• Men: 604 in every 1,000 had at least one false positive; 285 in every 1,000 underwent an invasive diagnostic procedure as a result. 604 − 285 = 319 people had a false positive without reaching an invasive procedure.
• Women: 488 in every 1,000 had at least one false positive; 221 underwent an invasive diagnostic procedure. 488 − 221 = 267 people had a false positive without reaching an invasive procedure.

⚠️ That "per 1,000" is participants in that trial's intervention arm, not Hong Kong people. As said above: the same test in populations of different prevalence has different positive predictive values. Converting an American trial's false positive rate into "per 1,000 Hong Kong people" would be manufacturing a local figure no source supports.

#What does scanning a healthy person find?

• Hong Kong data (2008): Lo GG et al., Hong Kong Med J 2008;14:90-6. 132 asymptomatic doctors (111 men, 21 women, mean age 56) had whole-body magnetic resonance imaging at a private hospital between October 2005 and February 2006. The results [Note 22]: 124 (94%) had a positive finding, of whom 24 (18%) needed further investigation; 5 (4%) were found to have a tumour, of whom 2 (1.5%) were confirmed malignant. ⚠️ The limits that must go with it: a sample of 132, all doctors, one institution, with the study stating its aim as feasibility rather than screening effectiveness, no follow-up, no control group, and nothing on whether those two malignancies benefited from being found. The 94% is about how much the machine sees, not how many people have disease.
• International data (2005): Furtado CD et al., Radiology. 2005 Nov;237(2):385-94. 1,192 people had whole-body computed tomography (mean age 54, scans between January and June 2000): 1,030 (86%) had at least one abnormal finding reported, 3,361 findings in all, an average of 2.8 each; and 445 (37%) were advised to have further investigation. Checking: 1030 ÷ 1192 = 0.864; 445 ÷ 1192 = 0.373; 3361 ÷ 1192 = 2.82. ⚠️ A sentence in the original's conclusion must go with it: in whole-body computed tomography screening, a large number of those examined had findings reported, and most findings were described as benign, requiring no further evaluation [Note 22]. ⚠️ This is also a scanner generation of twenty years ago.
• A meta-analysis published in 2026: Martins da Fonseca J et al., Eur Radiol. 2026 Mar;36(3):1813-1823. 10 studies, 9,024 asymptomatic people having whole-body magnetic resonance imaging, with a pooled detection rate for confirmed cancer of 1.57% (95% CI 1.22–2.03%), that is roughly 16 people per 1,000 (an interval of about 12 to 20). The original writes two sentences of its own [Note 22]: most of the studies had a moderate to serious risk of bias; and whole-body magnetic resonance imaging for opportunistic cancer detection in asymptomatic people has insufficient diagnostic yield, follow-up reporting and standardisation, and may lead to unnecessary investigations.

⚠️ Those three cannot be added together or used to correct one another — different equipment, different eras, different populations. Each describes the same shape: scan a healthy person and the commonest result is that something is found, and between "something found" and "disease" there are several layers.

#The radiation from computed tomography

The United States Food and Drug Administration's "Full-Body CT Scans - What You Need to Know" (page self-dated "Content current as of: 12/05/2017") states [Note 23]: the FDA is not at present aware of scientific evidence that whole-body scanning of asymptomatic people does those examined more good than harm; and an abnormal finding may not be serious, while a normal finding may be inaccurate.

The same agency's "What are the Radiation Risks from CT?" page offers a comparison that can be read directly [Note 23]: a computed tomography scan with an effective dose of 10 millisieverts may raise the chance of a fatal cancer by about one in two thousand; against which the natural incidence of fatal cancer in the United States population is about one in five, that is 400 in two thousand — so that the combined total risk may rise from 400 in two thousand to that same 400 in two thousand plus one.

But there is a sentence in the same passage that cannot be cut [Note 23]: that said, if a large population undergoes increasing numbers of computed tomography screening examinations of unclear benefit, this small individual increase in radiation-associated cancer risk could become a public health issue.

The dose table cited on the same page (reproduced by the FDA from McCollough CH et al., Mayo Clin Proc. 2015;90(10):1380-92): chest X-ray (posteroanterior) 0.02 millisieverts, CT head 2, CT chest 7, CT abdomen 8, coronary calcium CT 3, coronary CT angiography 16. ⚠️ The same page also states that actual doses may be two to three times larger or smaller than the estimates, so these figures cannot be added up one by one and multiplied back against that risk.

#The psychological effect after a false positive, with three years of follow-up data

Brodersen J, Siersma VD, Ann Fam Med. 2013 Mar-Apr;11(2):106-15 (PMID 23508596). 454 women with an abnormal mammography result, matched against twice that number with normal results at the same hospital on the same day, followed for three years [Note 24]: three years after being told they did not have cancer, the false positive group continued to report greater negative effects on all 12 psychosocial measures (all 12 pointing the same way, of which 4 reached P<0.01).

Both sides have to be said: the 12 measures point the same way, but only 4 reached P<0.01.

⚠️ If you are holding an "all normal" report and planning to think no more about your health this year, or holding an asterisk and unable to sleep: both need the same sentence — this piece of paper is not a verdict, it is a set of readings, to be read by a doctor together with your history.

#How are the packages on the Hong Kong market actually sold?

A Consumer Council survey of 2023 with a defined sampling frame found fees for comparable plans differing by more than 9 times, and no correspondence between "how many items" and "whether it is of any use"; and the pages published by another eighteen providers point the same way on date labelling and on package contents.

#One: the Consumer Council survey of 2023 — the only data in this section with a defined sampling frame

Every figure below is from the Consumer Council's press release of 15 May 2023 (the page self-dated 2023.05.15).

The sampling frame: in February and March 2023 the Council collected the service fees and information of 33 basic body check plans from the websites of 12 private hospitals or their affiliated medical centres and 14 private healthcare providers; another 5 providers did not reply, and Council staff then approached them as consumers to ask for the information.

• Price: the fees of the 33 plans ranged from $820 to $8,310, a spread of more than 9 times. ⚠️ Note that this range compares the lower of the fees each plan states for itself, not the list price.
• Dual pricing: more than 5 in ten plans (18) displayed 2 different fees, labelled for instance "original price / promotional price".
• Item coverage, with the two kinds of provider taken separately: among private healthcare providers, more than 9 in ten of their plans (15) offered fewer than half of the basic examination items, and 5 in ten of those (8) offered only 1 assessment item; among private hospitals the opposite held, with more than 9 in ten plans (16) containing half or more of the basic examination items.
• Why "the item count" cannot be compared directly: the Council recorded a plan that split a "liver function" test into 13 items, and another that split "blood cell analysis (complete blood picture)" into 14.
• Who does it and who explains it: about 3 in ten plans (10) stated that the examination would be carried out only by nurses, healthcare staff, health assistants, radiographers and/or laboratory staff. On whether a doctor explains the report, the Council's original states its denominator: setting aside the 2 plans that gave no information, 5 plans did not include a doctor explaining the report — that is 5 out of 31, not 5 out of 33.
• The Council's own closing, two sentences together: a general package-style examination may not fully reflect the state of the body; and where there is a persistent unexplained change in the body, a doctor should assess and diagnose it.

Taken together, those figures demonstrate one thing: two plans both badged "basic body check" can be, one of them, more than half of 8 basic assessment items, and the other only 1 item, and both are called a "body check plan". And at the same time another plan can write one "liver function" as 13 lines. So: the item count on a leaflet, how many things you actually had tested, and how many of them are of use to you are three different things.

⚠️ A finding of the same shape was made twenty-one years earlier: issue 304 of the Council's CHOICE magazine (the page self-dated 2002.02) recorded at least 12 private hospitals offering 62 plans, with the number of examination items ranging from 4 to more than 50. ⚠️ A CHOICE issue number is not a year — issue 304 is February 2002, and issue 559 is May 2023.

#Two: the pages published by another eighteen providers

The pages those eighteen providers publish themselves show three things: only four self-note an effective or updated date on the price page and have a source document this article holds, while ten do not; "more expensive" does not necessarily contain everything in the cheaper one; and entry-level packages almost invariably exclude tumour markers and ultrasound.

⚠️ Scope: all of the following is about the pages eighteen named providers published themselves on 2 August 2026, not about the Hong Kong market. The eighteen are: re:HEALTH, Mobile Medical, Medtimes, UMP, CUHK Medical Centre, Trinity Medical Centre, Hong Kong Baptist Hospital Day Medical Centre, Blue Care, Zenith Medical Centre, Tsuen Wan Adventist Hospital, Union Hospital, St Paul's Hospital, Quality HealthCare (QHMS), Hong Kong Adventist Hospital – Stubbs Road, Humansa, Gleneagles Hospital Hong Kong, Hong Kong Sanatorium & Hospital, and Matilda International Hospital. This platform does not rank or select any provider.

⚠️⚠️ This article does not reproduce the package prices of those eighteen providers. The reason is set out at item 4 of "What this article does not state" below: no per-provider source that a reader could check for themselves was obtained for any of those price figures; and an article about whether price labelling can be checked should not itself print a set of prices a reader equally cannot check. For price information, rely on what each provider's own website carries on the day.

#How dates are published

Within that same set of providers: four self-note an effective or updated date on the page or document carrying the prices and have a source document this article holds, and ten do not; UMP's "Health Check and Preventive Medicine" page (retrieved 2 August 2026) lists no body check package prices at all; and St Paul's Hospital has prices, but the two pages that should carry the item lists have no content. (⚠️ The UMP group also has an online store, whose prices are outside the scope above. Of the ten providers with no self-noted date, Humansa prints in its plan PDF a general statement about the right to adjust prices, but that is a general term rather than a label printed beside the price list stating the effective or updated date of the price list itself, and so is not counted among the four with a self-noted effective or updated date.)

⚠️ Zenith Medical Centre is an obstetrics and gynaecology specialist centre, and its website publishes no general body check package (no tumour markers, no chest X-ray, no electrocardiogram, no computed tomography). It appears in the list above only because it is one of the eighteen names this article listed.

⚠️ The "item count" on a provider's leaflet is not a comparable unit. A leaflet badged 65 items and one badged 110 items may differ only in how they split things up.

#Four findings on how prices are labelled

1. One provider carried the words "half price, limited time" on one of its plans, with no original price printed on the same page and no end date for the offer. A "half price" with neither a published original price nor a published deadline is a claim a reader cannot check.
2. One provider carried different promotional prices on its Chinese and English pages on the same day: for the same three plans, the promotional prices differed between the Chinese and English pages while the original prices agreed on both. So any citation of that provider's prices has to say which language version was being read.
3. One did use a comparison basis a reader can check: Medtimes prints an "individual item total" beside its promotional price — the sum of buying the same items one by one, rather than an original price with nothing behind it.
4. Validity periods and refund terms vary a great deal. One provider prints that a body check plan is generally valid for 6 months from the date payment is confirmed; another prints that all plan contents are fixed, and that where any examination in the plan is declined or not carried out for any reason, there will be no refund or substitution.

#Three findings on contents that readers least expect

• "More expensive" is not necessarily "everything in the cheaper one". Among these eighteen, one provider's fourth-tier package omits the chest X-ray and the seven tumour markers in its own third tier (replacing the X-ray with low-dose chest computed tomography); another has no chest X-ray in any of its three most expensive tiers; and a third swaps the resting electrocardiogram for an exercise electrocardiogram in its top tier. A reader assuming that dearer means more comprehensive would be wrong at three of these eighteen at least.
• Entry-level packages almost invariably exclude tumour markers and ultrasound, and computed tomography is usually an upgrade costing extra (one hospital, for instance, prints that for an additional charge one may upgrade to computed tomography coronary angiography or to low-dose chest computed tomography).
• One provider prints a footnote on its 120-item package: 「如若周日進行檢查，將轉為癌症指標篩查：鱗狀細胞癌抗原」 — if the examination is done on a Sunday, it changes to a cancer marker screen, squamous cell carcinoma antigen. Which is to say that on the same package, going on a Sunday swaps the chest X-ray for a blood tumour marker. So "the package includes X" is not a safe sentence away from its footnotes.

#Whether the fee includes an explanation — two providers have written it out themselves

One of the UK National Screening Committee's recommended questions is "what does the cost include? … will follow-up of results cost extra?" Providers in Hong Kong have answered it themselves: 「收費包括醫生解釋標準計劃的報告。如需進一步額外的講解及/或諮詢，或需收取額外診金。」 — the fee includes a doctor explaining the report of the standard plan, and any further explanation and/or consultation may attract an additional consultation fee. And: 「上述收費不包括藥物和治療費用。」 — the fees above do not include the cost of drugs and treatment.

#Three: where Hong Kong's regulatory gap is

• The provisions of the Private Healthcare Facilities Ordinance (Chapter 633) relating to price transparency have still not come into operation (Consumer Council, 6 March 2025: 「不過，現時《條例》中與收費透明度相關的條文仍未生效。」), and the pilot scheme now running is voluntary. So there is no institutional support for a reader comparing packages on a common basis in the first place.
• The Medical Council's Code of Professional Conduct (revised October 2022) has no provision aimed at commercial body check packages; but it does have one stating the nature of this relationship: section 1.2.1, 「當醫生為任何人士進行健康檢查時，雙方即時建立起醫生與病人的關係」. Which is to say that a body check is not a retail transaction but a doctor-patient relationship. The code also prohibits touting.

#Four: some in Hong Kong family medicine have written on it, but not as a College position

The following are signed articles published in the Hong Kong Practitioner, representing the authors' personal opinions and not the position of the Hong Kong College of Family Physicians [Note 25]:

• Hui An-tung, editorial of April 2005: anyone offered any screening programme should have a properly designed scheme with sensible intervals, rather than an ad hoc assembled examination package.
• Chan Siu-bun, Wong Wai-bun and Tang Kuen-yan, December 2024 and March 2025: in recent years some have promoted whole-body screening with computed tomography, positron emission tomography, or both, without strong supporting evidence… the real benefit of screening is early treatment, not merely early detection.

That last sentence is the core of the whole subject: early detection and early treatment are not the same thing. Finding something that would never have harmed you does not make you live longer; that is overdiagnosis. Tsuen Wan Adventist Hospital's own article uses the word: 「甲狀腺沒有可疑症狀亦無須照甲狀腺超聲波，以免因過度診斷(overdiagnoisis)，導致可能要接受不必要的治療甚至手術。」 — where there are no suspicious thyroid symptoms there is no need for a thyroid ultrasound, lest overdiagnosis lead to unnecessary treatment or even surgery. ("overdiagnoisis" is that page's own spelling, reproduced as found.) That sentence points the same way as the expert working group's 2018 「不建議為一般風險的無症狀人士作甲狀腺癌篩查。」

⚠️ If you plan to choose a package by item count and price: neither number is reliable — the item count is not a comparable unit, and among these eighteen the relationship between price and what is included does not increase in one direction.

#What can you ask before buying?

The UK National Screening Committee published a list of questions on 21 November 2023, public guidance written specifically about screening sold by private providers. The five questions are reproduced in full at [Note 26]; the substance:

1. What benefit will this test bring? Is there evidence that it will help you avoid an important health problem in future? If it only claims to give you peace of mind, a fitness check and some good advice about nutrition and exercise may be a better option.
2. What does the cost include? Are the costs clear? Is there a pressuring "book now for a promotional price" offer? Will follow-up of results cost extra, and if so how much?
3. Could this test do more harm than good? Some tests carry risks in themselves. Does the provider give balanced information about what the test involves and its potential harms? A screening provider should give those tested the opportunity to discuss the balance of benefits and harms with a healthcare professional.
4. What happens if the test finds something? If screening finds a problem, is there an effective and acceptable treatment? If the answer is no, would you still want the test?
5. What happens if the test does not give a clear result? What support will the provider give? Will another test be needed, and what, at what cost, and by whom?

Two further questions are specific to England and cannot be carried over to Hong Kong: one asks whether the test is already provided free by the NHS, and the other whether the provider is registered with the Care Quality Commission in England. Hong Kong's corresponding regulatory arrangement is the licensing and code of practice regime under the Private Healthcare Facilities Ordinance (Chapter 633), and this article makes no statement about the corresponding Hong Kong answers.

⚠️ Before listing the harms, the same guidance writes two sentences pointing the other way, and both have to be given [Note 1]: good quality, evidence-based screening programmes do save lives and improve health outcomes — they do it by finding people who have a higher chance of developing a defined condition and offering them information, further tests and timely effective treatment; however, all screening can do harm as well as provide benefits, and good screening does more good than harm.

So the harms listed below are about the practice of testing a great many things at one go, and are not saying that the screenings in table two and the Live Well Plan above, with their defined target groups and defined intervals, should not be done.

The same guidance also lists the harms of screening. ⚠️ The original opens with "include", so it is not a closed list. The full text is at [Note 1]; the five are: even the best screening test will not be wholly accurate; false positives are inevitable, bringing unnecessary worry and follow-up tests that may carry risks of complications; false negatives are equally inevitable, giving false reassurance so that signs may later be ignored; screening can lead to overdiagnosis and overtreatment — uncovering conditions that would never have caused a problem in a person's lifetime but which, once found, require treatment; and the chance of harm rises if the screening test and programme is not delivered to high quality standards to everyone.

The same guidance also draws a distinction between having a test and having a programme, and this is the largest structural difference between a commercial package and a public screening programme: a screening test alone is of no benefit unless appropriate support, advice and, if appropriate, intervention and follow-up take place as part of a seamless process [Note 1].

⚠️ The same guidance opens a separate section on the drawbacks of commercially motivated screening — three of them, not one [Note 1]: first, they often only offer a test, so that if the person tested receives an abnormal result it is up to them to seek advice, possible further investigation or treatment; second, companies may offer screening that is not evidence-based — meaning there are no reliable studies confirming that it improves health outcomes for those screened — and companies often promote screening as simply offering peace of mind; third, there is often no quality assurance, meaning the same test might not be the same everywhere.

⚠️ The last sentence of the first drawback, about the tests needing to be repeated by the NHS, is an English institutional arrangement and cannot be carried over to Hong Kong; the second and third are not institutional and are about the commercially motivated shape itself. Whether there is evidence, and whether there is quality assurance, are two things invisible on a leaflet — a leaflet lists item names and prices.

The Hong Kong Consumer Council's press release of 14 July 2016 (which states that it was written after seeking professional views from the Department of Health, the Hong Kong College of Pathologists and the Hong Kong Medical Association) wrote one sentence on the same point [Note 7]: all laboratory tests must be combined with a doctor's clinical examination before a meaningful analysis and risk assessment can be made, so whether or not a laboratory result is normal it should be interpreted by a doctor, to avoid the results being misunderstood.

⚠️ That press release page is self-dated 14 July 2016 and is now ten years old. It is the only Hong Kong document this article has found carrying the views of the Department of Health, the Hong Kong College of Pathologists and the Hong Kong Medical Association on the limitations of body check items; it must be cited with its date, and cannot be taken as current government advice.

#What to do next

This article will not tell you which package to buy or which items to have, but it can convert "how often" into a few questions you can answer.

First, establish which of the two things you are asking about. If you have symptoms — whatever they are — none of the timetables above applies, and the path is a doctor. Both the UK National Screening Committee and the Centre for Health Protection have written the same sentence on this.

Second, if you have no symptoms, convert "how often should I have a check-up" into "what age am I, am I a man or a woman, and therefore which items have I reached". That question has an official answer, and it is one page: the Primary Healthcare Commission's Live Well Plan charts for men and for women. Blood pressure at least once every two years from 18; blood glucose and blood lipids at least once every three years from the 45 to 49 band; colorectal cancer from 50 to 75; cervical cancer from 25 to 64; breast cancer from 44 to 69, starting with the official risk assessment tool (how that tool is used is in our article on breast cancer screening). The chart states for itself that it is not exhaustive, and the column on its right sets out who should start earlier or go more frequently — that column is for a doctor to judge.

Third, if you decide to buy a package, throw away the item count as a measure. The Consumer Council recorded a plan counting a "liver function" test as 13 items; and among the eighteen providers this article looked at, at least three had a dearer package missing something the cheaper one had. Ask the UK National Screening Committee's five questions instead — particularly whether following up a result costs extra, and whether, if something is found, there is an effective and acceptable treatment.

Fourth, watch the words "average risk". Everything in the "not recommended" table one is the "average risk" column only. If you have chronic hepatitis B or C, cirrhosis, a relevant family history or a pathogenic gene mutation, you are not in that column, and the same document has different, sometimes opposite, advice for you. Which column you are in is for a doctor to judge, not for you to match against a table. The full accounts of each screening are in our article on breast cancer screening and our three further articles on cervical cancer screening, colorectal cancer screening and endoscopy.

Fifth, do not read the report yourself. In a group of healthy people, having at least one out-of-range value is the norm — on the 95% reference range laboratories customarily use, the chance that a healthy person's 20-item biochemistry report is entirely inside the ranges is only about 36%. But whether something is out of range and by how much are two different things, and telling them apart is the doctor's work. The Council's sentence of 2016 puts it most directly: whether or not a laboratory result is normal, it should be interpreted by a doctor.

A last sentence: this article gives no number anywhere for "how often to have a body check", not because the search was incomplete, but because not one of the Hong Kong official documents listed one by one here has ever set an interval for "a package". What has intervals is items, not packages.

#Frequently asked questions

So should I have a body check every year or not?

This article makes no recommendation on individual circumstances. What can be said is this: the Hong Kong government publishes item-by-item intervals — the Health Bureau Primary Healthcare Commission's Live Well Plan charts for men and for women (foot self-noted "Health Bureau (01/2026)") lay out on one page the age bands and intervals for blood pressure, blood glucose, blood lipids, cancer screening, vaccination, body weight and oral health — but not one of the official documents cited here has ever set any interval for "a package covering several organ systems". And the official intervals for individual items run from six months (high normal blood pressure) to ten years (colonoscopy), with no common answer. The Centre for Health Protection's men's body check page answers "when to test again" with 「要聽取報告，並要求醫生給予你建議如何跟進問題和下次檢查的時間。」 and "what to test" with 「醫生會按個別人士的年齡、性別、健康狀況和家庭健康背景等而建議所需要檢查的項目。」 Both hand it back to a doctor.

The expert working group says liver cancer screening is not recommended — what about me, a hepatitis B carrier?

Everything in the "not recommended" table one is the "average risk" column of the summary table only. Item 5 on liver cancer in the "higher risk" column of the same document reads: 「慢性乙型肝炎患者、丙型肝炎患者或任何原因引致肝硬化的人士，患肝細胞癌的風險較高。此類高風險人士應諮詢醫生有關每 6 個月定期進行超聲波及甲胎蛋白檢測的意見。」 — people with chronic hepatitis B, hepatitis C or cirrhosis of any cause are at higher risk of hepatocellular carcinoma, and such high-risk people should seek a doctor's advice about regular ultrasound and alpha-fetoprotein testing every six months. The two columns point in different directions, and which one you are in is for a doctor to judge. The Primary Healthcare Commission also now runs a Hepatitis B Co-Care Scheme.

Does more items mean more comprehensive?

An item count is not a comparable unit. The Consumer Council's survey of 15 May 2023 recorded a body check plan that split a "liver function" test into 13 items, and another that split "blood cell analysis (complete blood picture)" into 14; and the same survey found that among the 33 plans, 8 of the private healthcare providers' offered only 1 assessment item. And among another eighteen providers' own published pages, at least three had a dearer package missing something the cheaper one had. Mechanically, every independent test added adds a chance of being wrong: on the 95% reference range laboratories customarily use, the chance that a healthy person's 20-item biochemistry report is entirely inside the ranges is only about 36%. ⚠️ That calculation carries the limits the original sets out for itself; see above.

Does having tumour markers mean I have been screened for cancer?

The Consumer Council's press release of 14 July 2016 cites professional opinion: 「目前並沒有任何｢腫瘤標記｣測試具備足夠的敏感性和特異性，可單獨用作癌症篩查。」 — no "tumour marker" test at present has sufficient sensitivity and specificity to be used alone as a cancer screening test. The expert working group also states in terms 「不建議為一般風險的無症狀人士進行胰臟癌篩查（包括使用血清生物標記CA19.9 進行檢測）。」 (2022). ⚠️ And on pancreatic cancer, being at "higher risk" does not reverse the answer: the higher-risk column of the same document also reads 「鑑於現有證據不足，不建議為較高風險人士進行劃一的胰臟癌篩查。」

My package has a prostate-specific antigen test or a digital rectal examination — does that count as prostate cancer screening?

The expert working group's position of 2026 is 「未有足夠科學證據支持或反對為無症狀男士進行全民前列腺癌篩查。」 — neither side has been settled, which is not "do not do it". But three further sentences follow in the same item: 「一般而言，建議採取的篩查方法為前列腺特異抗原血液測試。開始和停止進行篩查的年齡，以及篩查間距，均應按個人情況而定。肛門指檢不宜作為單一的前列腺癌篩查方法。」 So: if it is done, the method is the PSA blood test; digital rectal examination on its own is not suitable as screening; and the ages to start and stop and the interval are handed in terms to individual circumstances, with no interval set.

All my results are normal — does that mean I am healthy?

No. The Centre for Health Protection leaflet (「二零二五年三月」): 「所有篩查測試都有其局限性，也不是百分百準確。」 The NHS (reviewed 30 July 2024): even if your screening result is normal or negative, you may still go on to develop the condition. If you have symptoms, see a doctor; a screening report cannot stand in for that step.

Is a whole-body CT or a whole-body MRI worth having?

This article makes no recommendation on individual circumstances, but it can set out what each source says for itself: the United States Food and Drug Administration (page self-dated 5 December 2017) states that it is not aware of scientific evidence that whole-body scanning of asymptomatic people does more good than harm; a meta-analysis of 2026 covering 9,024 asymptomatic people found a pooled cancer detection rate of 1.57% and stated that most of its studies had a moderate to serious risk of bias; and a study of 2008 covering 132 asymptomatic Hong Kong doctors having whole-body magnetic resonance imaging found 94% with a positive finding, 18% needing further investigation and 1.5% confirmed malignant. These figures cannot be converted into one another.

Blood pressure — once a year or once every two years?

Both have sources, but their shapes differ. The Consumer Council (2023.05.15) writes that an average person should have a hypertension check at least 1 time a year, a flat number. The Centre for Health Protection press release (17 May 2026), citing the Hong Kong Reference Framework for Hypertension Care, writes that adults aged 18 or above should have their blood pressure measured at least once every two years, and the reference framework's own table then narrows that by this reading (optimal, within two years; normal, yearly; high normal, six months). ⚠️ And there are notes under that table governing the interval column: where the systolic and diastolic categories differ, follow the higher category, and the blood pressure may be rechecked at the shorter interval. So a reading like 118/86 cannot be read off the "optimal" row as "within two years".

Can Elderly Health Care Vouchers be used for a body check?

The "Services covered" section of the voucher scheme's frequently asked questions states 「醫療券可用於預防性及治療性的服務，但不可用來純粹購買物品」 — vouchers may be used for preventive and curative services but not for the purchase of goods alone. ⚠️ The place on that page that prints the words for "body check" in terms is item 41, on the restrictions applying to the reward under the Elderly Health Care Voucher Reward Pilot Scheme — that sentence is about the restrictions on the $500 reward, not a list of the service scope of the vouchers themselves. Separately, whether a particular provider accepts them and on what additional conditions is something this article makes no statement about for any provider; ask the provider directly.

Is there a government-subsidised body check in Hong Kong?

There are two schemes subsidising screening for asymptomatic adults, and neither is a package. The Chronic Disease Co-Care Scheme is for Hong Kong residents aged 45 or above 「沒有已被確診患有糖尿病或高血壓」, and its screening covers diabetes mellitus and hypertension, with blood lipids added from 28 March 2025. The Hepatitis B Co-Care Scheme is for Hong Kong residents born in or before 1988 whose family member or sexual partner is a chronic hepatitis B carrier, who are not themselves diagnosed and have no symptoms, and who have never completed the full hepatitis B vaccination course. On co-payment, cardiovascular disease risk factor screening is 「不多於$120」 and hepatitis B screening 「不多於$180」, both one-off co-payments for the screening stage; ⚠️ the treatment stage has co-payments of its own (the government suggests $150 per consultation, nurse clinic $80, optometrist or physiotherapist $150, dietitian or podiatrist $380, laboratory tests charged separately, and $250 per Hospital Authority medical specialist consultation under two-way referral). Elderly Health Care Vouchers apply.

#Notes: the official originals

[Note 1] UK National Screening Committee guidance of 21 November 2023: 「Screening tests are not 100% accurate and do not provide a diagnosis.」「Screening is not for people who have symptoms. People who have symptoms should always consult their GP.」 The opening of section 1: 「Good quality, evidence-based screening programmes do save lives and improve health outcomes. They do this by finding people who have a higher chance of developing a defined condition and offering them information, further tests and timely effective treatment.」「However, all screening can do harm as well as provide benefits. Good screening does more good than harm.」 The harms section: 「The harms and limitations of all screening include: Even the best screening test will not be 100% accurate. Tests may not always give clear-cut or reliable answers. They can lead to false reassurance, false alarms, and the discovery of uncertain findings. / False positive results are inevitable in screening. This is when a screening test shows up a potential condition, but further tests reveal there is not a problem. This leads to unnecessary worry, and follow-up tests and investigations which may carry risks of complications. / False negative results are also inevitable in screening. This is where a condition exists or is soon to arise, but the test result is normal. This means people are falsely reassured and may ignore signs or symptoms later, thinking everything must be fine. This can lead to delays in diagnosis and treatment. / Screening can lead to overdiagnosis and overtreatment. This is where screening uncovers conditions which would not have led to a problem in a person's lifetime but which, once found, require treatment. This means people are treated unnecessarily, and sometimes suffer complications from medications, or from surgery. / The chance of harms rises if the screening test and programme is not delivered to high quality standards to everyone. Quality assurance is critical.」 And: 「A screening test alone is of no benefit unless appropriate support, advice and, if appropriate, intervention and follow-up, take place as part of a seamless process.」 The commercial screening section: 「Drawbacks of commercially motivated screening include: Often they only offer a test. If an individual then receives an abnormal finding from the test, it is up to them to seek any advice, possible further investigation or treatment. Often the tests will need to be repeated by the NHS. / Companies may offer screening that is not evidence-based. This means there are no reliable studies confirming that it leads to improved health outcomes for those screened. Companies often promote screening as simply offering peace of mind. / Often there is no quality assurance, meaning the tests might not be the same everywhere.」

[Note 2] Centre for Health Protection of the Department of Health, Cancer Prevention and Screening leaflet (self-dated 「二零二五年三月」): 「癌症篩查的目的，就是在未出現任何症狀前，及早發現患上癌症或癌前病變的人士，以便及早治療。」「任何人士如出現懷疑患癌的症狀或身體變化，應盡快約見醫生作適當診斷和接受治療。」「所有篩查測試都有其局限性，也不是百分百準確。」

[Note 3] Cochrane review of 2019 (CD009009): 「We defined health checks as screening for more than one disease or risk factor in more than one organ system.」

[Note 4] WHO Regional Office for Europe screening guide of 2020: 「When more than one test is offered as part of a bundle or health check, before it will be an effective screening programme: each test should be subject to the same stringent criteria used to determine whether to start a screening programme; each test should be part of a pathway of care; and each test should be provided in a way that fulfils the requirements of the green cells in Table 1.」 And: 「Carrying out multiple screening tests at the same time may reduce costs or simplify the programme, but each test needs to be assessed on its own merits.」

[Note 5] Dickinson JA, Chee S, Hong Kong Medical Journal 2000;6:415-22: 「The concept of an annual physical examination was first proposed by the American Medical Association in 1922. In recent years, however, concerns about the value of such activities have led to evidence-based appraisal, first done systematically by the Canadian Task Force on the Periodic Health Examination.」「These task forces pointed out that performing the same interventions on all patients annually is not an effective approach. They suggested that the 'annual check-up' should be abandoned, and the American Medical Association withdrew support for this policy in 1983. Instead, they recommended that a series of age-specific 'health protection packages' should be offered, usually during the course of medical visits for other reasons and that the content of such packages should be closely scrutinised and demonstrated to be valuable.」「Basic packages offered an average of 16 tests for HK$2670 and advanced packages an average of 26 tests for HK$6244.」「Table 2 shows that one third of the tests in basic packages had proven benefit, 17% were of uncertain benefit, and approximately 13% were possibly harmful. About one third were not rated by the task forces, presumably largely because there are insufficient reasons to include them in preventive services.」「In this study, we were deliberately generous and took an optimistic view of the potential for benefit. Many experts would be more pessimistic.」「It appears that institutions offering these services consider that 'more is better'. The widespread advertising of these packages may wrongly educate the population that these are effective preventive services and that better preventive services are a function of willingness to spend.」 And: 「There is no formal guidance from any authoritative body in Hong Kong」

[Note 6] WHO Regional Office for Europe screening guide of 2020: 「the ability of the screening test to identify people with the condition as positive」「the ability of the screening test to identify healthy people as negative」「the likelihood that the screening participant has the condition that screening targets when the test is positive」「Both the positive predictive value and the negative predictive value of a test depend on the prevalence of the condition (how common a condition is in the screened population) … Using the same type of screening test in different populations will therefore give different results.」「When a condition is less common in a country (low prevalence), the positive predictive value is lower. This means that there will be more false positives than in a country with a higher prevalence of the condition, even though the sensitivity and specificity are the same.」

[Note 7] Consumer Council press release of 14 July 2016: 「報告引述專家意見指，市面常見的健康檢查套餐多屬「無條件」式的檢查，即並非按醫學判斷及臨床需要而定，只是為沒有徵狀人士透過大包圍式的檢查、化驗，希望及早發現隱疾，做法未必奏效。」「以｢靜態或運動心電圖｣作為檢測冠狀動脈疾病的檢查，在發病率低和沒有任何徵狀的人士身上，出現假陽性檢查結果的比率高。以｢胸肺X光｣作為篩查肺癌的工具，其敏感性不足，出現假陰性檢查結果的機率較高。」「目前並沒有任何｢腫瘤標記｣測試具備足夠的敏感性和特異性，可單獨用作癌症篩查。」「消委會強調，所有化驗必須配合醫生的臨床身體檢查，才能作出有意義的分析和風險評估，故無論化驗結果正常與否亦應由醫生解讀，以免錯誤理解相關檢驗結果。」

[Note 8] Australian Prescriber, 1 April 2009, "Pitfalls in interpreting laboratory results": 「By tradition, laboratories quote a reference range including 95% of the reference population.」「Why normal people often have abnormal results — A multiple biochemical analysis can be performed by one machine and produce 20 results. Assuming these results were all independent of each other (which they are not) and that results from the reference population are normally distributed (which they may not be), only 36% of normal people will have all 20 results in the reference range. There will be 64% with at least one abnormal result」「However, the more abnormal the result and the more related tests are abnormal, the more likely the abnormality is clinically significant.」「Some results vary so much within the population that the laboratory may quote a reference range that includes a smaller proportion of the population. For example, the reference range commonly quoted for serum insulin may only include results within one standard deviation above and one standard deviation below the mean value. This includes 68% of the reference population. In this case, 16% of normal people will have 'abnormal' high insulin and 16% will have 'abnormal' low insulin according to the quoted reference range. Serum insulin is therefore not a useful test for assessing 'insulin resistance'.」

[Note 9] Cochrane review of 2019 (CD009009): 「Health checks have little or no effect on total mortality (risk ratio (RR) 1.00, 95% confidence interval (CI) 0.97 to 1.03; 11 trials; 233,298 participants and 21,535 deaths; high-certainty evidence, I2 = 0%), or cancer mortality (RR 1.01, 95% CI 0.92 to 1.12; 8 trials; 139,290 participants and 3663 deaths; high-certainty evidence, I2 = 33%), and probably have little or no effect on cardiovascular mortality (RR 1.05, 95% CI 0.94 to 1.16; 9 trials; 170,227 participants and 6237 deaths; moderate-certainty evidence; I2 = 65%).」「AUTHORS' CONCLUSIONS: General health checks are unlikely to be beneficial.」「We propose that one reason for the apparent lack of effect may be that primary care physicians already identify and intervene when they suspect a patient to be at high risk of developing disease when they see them for other reasons.」「adults unselected for disease or risk factors」「We did not include geriatric trials.」

[Note 10] Centre for Health Protection of the Department of Health, Summary of Cancer Screening Recommendations of the Cancer Expert Working Group on Cancer Prevention and Screening (document self-noted 2026). Item 5 of the liver cancer higher-risk column: 「慢性乙型肝炎患者、丙型肝炎患者或任何原因引致肝硬化的人士，患肝細胞癌的風險較高。此類高風險人士應諮詢醫生有關每 6 個月定期進行超聲波及甲胎蛋白檢測的意見。」 The lung cancer higher-risk column: 「不建議較高風險的無症狀人士接受以胸肺X 光檢查或痰液細胞檢查方式進行肺癌篩查。」 Item 2 on pancreatic cancer: 「鑑於現有證據不足，不建議為較高風險人士進行劃一的胰臟癌篩查。至於因為有強烈的胰臟癌家族病史、有特定的遺傳綜合症或某些遺傳易感性特徴而令罹患胰臟癌風險大增的人士，可考慮諮詢醫生意見作個別評估。」 Item 3 on prostate cancer: 「無症狀男士若考慮接受前列腺癌篩查，應與臨牀醫護人員討論篩查的潛在利弊，以便作出知情選擇。一般而言，建議採取的篩查方法為前列腺特異抗原血液測試。開始和停止進行篩查的年齡，以及篩查間距，均應按個人情況而定。肛門指檢不宜作為單一的前列腺癌篩查方法。」 The last page: 「重要注意事項：接受癌症篩查前應與你的醫療服務提供者討論相關的好處和風險。」 The lung cancer section also carries: 「由於目前尚未有充分證據證明此等準則適用於本地情況，因此重度吸煙人士應與醫生商討接受低輻射量電腦掃描篩查的利弊」.

[Note 11] The same, items 2 to 4 of the colorectal cancer higher-risk column: 「帶有「連氏綜合症」基因突變的人士，從 25 歲起，每一至兩年接受一次大腸鏡檢查。」「帶有「家族性大腸腺瘜肉病」基因突變的人士，從12 歲起，每兩年接受一次乙狀結腸鏡檢查。」「有一位直系親屬於60 歲或以前確診大腸癌或有兩位或以上的直系親屬患有大腸癌（不論確診歲數），但沒有遺傳性的腸病的人士從40 歲起或按患上大腸癌最年輕親屬的確診年齡計算早十年起(但不早於12 歲)，每五年接受一次大腸鏡檢查。作為另一選擇，相關人士在了解大便隱血測試與大腸鏡檢查相關的利弊後，可考慮每一或兩年進行大便隱血測試作為大腸癌篩查。」 Items 6 to 7 of the cervical cancer higher-risk column: 「21 至 24 歲而曾有性經驗的婦女， 如有感染／持續感染HPV 或患子宮頸癌的風險因素，會被視為較高風險人士。她們應按照醫生的評估和建議接受篩查。」「其他較高風險的婦女須由醫生評估，並可能須接受較頻密的篩查。」 Item 6 of the breast cancer moderate-risk column: 「建議乳癌風險屬中等的婦女（即只有一名直系女性親屬在 50 歲或以前確診患上乳癌；或有兩名直系女性親屬曾在 50 歲之後確診患上乳癌）每兩年接受一次乳房 X 光造影篩查。不建議以磁力共振掃描造影為中等風險的婦女進行乳癌篩查。」 The footnote to the breast cancer recommendation column: 「*包括有直系親屬曾患乳癌、曾診斷患有良性乳腺疾病、從未生育或第一次生產年齡晚、初經年齡早、體重指數偏高和缺乏體能活動」

[Note 12] Primary Healthcare Commission, "Eligibility". The Chronic Disease Co-Care Scheme: 「45歲或以上香港居民*；及／沒有已被確診患有糖尿病或高血壓」. The Hepatitis B Co-Care Scheme: 「於一九八八年（即初生嬰兒普及乙型肝炎疫苗注射計劃之推出年份 ）或以前出生的香港居民* ; 及／其家庭成員（包括父母、兄弟姐妹及子女）或性伴侶為慢性乙型肝炎患者；及／沒有已被確診患有慢性乙型肝炎及並無相關病徵；及／不曾完成整個乙型肝炎疫苗接種程序」. What the screening stage covers: 「由家庭醫生評估及安排篩查化驗／由家庭醫生轉介到指定醫務化驗所抽血／由家庭醫生解釋化驗報告及診斷結果，安排合適的健康管理方案／由地區康健中心安排免費乙型肝炎表面抗原快速測試(只適用於乙肝共治計劃)」.

[Note 13] Elderly Health Care Voucher Scheme frequently asked questions page. The answer to item 7: 「醫療券可用於預防性及治療性的服務，但不可用來純粹購買物品，如藥物、眼鏡、海味、個人護理用品、食品或醫療用品。」 Item 41: 「長者醫療券獎賞先導計劃旨在鼓勵長者更有效使用私營基層醫療服務，故此獎賞只可用於預防疾病或管理健康等的特定基層醫療用途，包括：⋯⋯西醫：健康評估、驗身、篩檢、防疫注射、處方預防藥物及治理慢性疾病等」. Item 39: 「合資格長者如在同一年度累計使用1,000元或以上醫療券於預防疾病和管理健康等特定基層醫療用途，即會自動獲發放500元獎賞至其醫療券戶口內作同樣用途，使用期限為下一個曆年年底，逾期作廢。」

[Note 14] Hong Kong Reference Framework for Life Course Preventive Care in Primary Healthcare, core document, Chapter 5: 「It focuses on preventive activities applicable to general asymptomatic (low risk) population with additional information about individual's risk assessment on vaccination and cancer screening for person at higher risk.」「(d) patient education tool」「The chart is not meant to be exhaustive and will be regularly updated according to latest evidence.」 The foot of the chart: 「Please note that the above list is not exhaustive; Other preventive care activities may also be considered.」

[Note 15] Life Course Preventive Care Plan – Men, the "High risk factors for metabolic diseases and hypertension" column: 「Smoking history; Sedentary lifestyle; Overweight/ obesity; Central obesity (waist circumference ≥90cm); Pre-diabetes; Family history of diabetes or hypertension; Family history of heart disease」. The same column on the women's chart reads 「waist circumference ≥80cm」 and adds 「History of polycystic ovary syndrome; History of gestational diabetes; History of pre-eclampsia during pregnancy; History of delivery of baby weighing ≥4kg」. The heading of the cancer screening column: 「Individuals at higher risk will require screening starting at an earlier age and/or more frequently」

[Note 16] Hong Kong Reference Framework for Hypertension Care for Adults in Primary Care Settings, Chinese version, Chapter 7: 「建議　最少每兩年一次為所有18 歲或以上成人量度血壓。」 Three of the five notes under table 2: 「註1. 血壓的分類是基於坐著量度的診間血壓。如收縮壓和舒張壓水平在不同的分類， 類別較高的分類應被使用為血壓水平的分類。」「註2. 如收縮壓和舒張壓的分類有別，可按較短的覆診相隔時間覆檢血壓。」「註3. 調整覆診相隔時間可根據有關過往血壓度數、有否其他心血管疾病風險因素或有否目標器官疾病等而定。」

[Note 17] Centre for Health Protection press release (17 May 2026): 「根據基層醫療署推出的《香港高血壓參考概覽 - 成年高血壓患者在基層醫療的護理》，18歲或以上的成年人應每兩年最少量度血壓一次。個別人士可能因應其血壓水平、年齡、患冠心病的綜合風險，以及醫生建議而需要更頻密地監測血壓。」

[Note 18] Centre for Health Protection, "Men's body check — an introduction to men's health checks" page: 「醫生會按個別人士的年齡、性別、健康狀況和家庭健康背景等而建議所需要檢查的項目。」「要聽取報告，並要求醫生給予你建議如何跟進問題和下次檢查的時間。」

[Note 19] NHS Health Check page (Page last reviewed: 14 August 2023): 「The NHS Health Check is a free check-up of the health of your heart and blood vessels (cardiovascular health).」「The check is for people who are aged 40 to 74 who do not have any of the following pre-existing conditions: heart disease / chronic kidney disease / diabetes / high blood pressure (hypertension) …」「If you're aged 40 to 74 and do not have a pre-existing health condition, you should be invited to an NHS Health Check by your GP or local council every 5 years.」

[Note 20] NHS screening overview page (Page last reviewed: 30 July 2024): 「If you get a normal result after a screening test (a 'screen negative' result), this means you are at low risk of having the condition you were screened for. This does not mean you will never develop the condition in the future, just that you are low risk at the moment.」「Even if your screening test result is normal or negative (meaning you are not at high risk), you could still go on to develop the condition.」

[Note 21] Croswell JM et al., Ann Fam Med 2009;7(3):212-22: 「After 14 tests, the cumulative risk of having at least 1 false-positive screening test is 60.4% (95% CI, 59.8%-61.0%) for men, and 48.8% (95% CI, 48.1%-49.4%) for women. The cumulative risk after 14 tests of undergoing an invasive diagnostic procedure prompted by a false-positive test is 28.5% (CI, 27.8%-29.3%) for men and 22.1% (95% CI, 21.4%-22.7%) for women.」

[Note 22] Lo GG et al., Hong Kong Med J 2008;14:90-6: 「A total of 124 (94%) subjects had positive findings, of whom 24 (18%) had further workup. Five (4%) subjects were found to have tumours, of which two (1.5%) were proven malignant.」 Furtado CD et al., Radiology 2005;237(2):385-94, conclusion: 「With whole-body CT screening, findings were detected in a large number of subjects, and most findings were benign by description and required no further evaluation.」 Martins da Fonseca J et al., Eur Radiol 2026;36(3):1813-1823: 「Most studies had a moderate to serious risk of bias.」「whole-body MRI lacks sufficient diagnostic yield, follow-up reports and standardization for opportunistic cancer detection in asymptomatic individuals and may lead to unnecessary investigations.」

[Note 23] United States Food and Drug Administration, "Full-Body CT Scans - What You Need to Know" (Content current as of: 12/05/2017): 「at this time the Food and Drug Administration (FDA) knows of no scientific evidence demonstrating that whole-body scanning of individuals without symptoms provides more benefit than harm to people being screened.」「An abnormal finding, for example, may not be a serious one, and a normal finding may be inaccurate.」 "What are the Radiation Risks from CT?": 「A CT examination with an effective dose of 10 millisieverts … may be associated with an increase in the possibility of fatal cancer of approximately 1 chance in 2000. This increase … can be compared to the natural incidence of fatal cancer in the U.S. population, about 1 chance in 5 (equal to 400 chances in 2000). … the total risk may increase from 400 chances in 2000 to 401 chances in 2000.」「Nevertheless, this small increase in radiation-associated cancer risk for an individual can become a public health concern if large numbers of people undergo increased numbers of CT screening procedures of uncertain benefit.」 And: 「could be two or three times larger or smaller than the estimates」

[Note 24] Brodersen J, Siersma VD, Ann Fam Med 2013;11(2):106-15: 「Three years after being declared free of cancer, women with false-positive results consistently reported greater negative psychosocial consequences compared with women who had normal findings in all 12 psychosocial outcomes (Δ >0 for 12 of 12 outcomes; P <.01 for 4 of 12 outcomes).」

[Note 25] Signed articles in the Hong Kong Practitioner. Hui An-tung, editorial of April 2005: 「any individual being offered any screening programme should have a well devised plan with rational screening intervals, rather than as ad hoc check-up packages.」 Chan Siu-bun, Wong Wai-bun and Tang Kuen-yan, December 2024 and March 2025: 「Recently, some have advocated using CT, PET, or PET/CT for whole-body screening without strong supporting evidence… The real benefit of screening is early treatment, not just early detection.」

[Note 26] The question list in the UK National Screening Committee guidance of 21 November 2023: 「What would be the benefits of having the test? Is there any evidence that the test can lead to avoidance of an important health problem some time in the future? If the test only claims to offer peace of mind, then a fitness check and good advice about nutrition and physical activity might be a better option.」「What do the fees cover? Are the fees clear? Is there a pressurising 'book now for a reduced price' offer? Will the company charge extra to follow up results? If so, how much extra will it charge?」「Can the test do more harm than good? Some tests carry a risk in themselves. Has the company provided balanced information about what the test involves and any potential harms? Are the potential benefits properly explained? … Screening providers should offer the chance for individuals to discuss the balance of benefits and harms with a health professional.」「What if the test picks something up? If screening picks up a problem, is there a treatment available that is effective and acceptable? If the answer is 'no', would you want to have the test at all?」「What if there are no clear results? Is there a chance that the test will produce no clear result(s)? If so, what support will the company provide, will more tests be needed, what will they involve, how much will they cost and who will deliver them?」

#What this article does not state

Each of the following is something this article set out to answer but omitted for want of adequate sources:

1. How many people in Hong Kong actually have body checks, and how often. The Census and Statistics Department's thematic household survey has a report on knowledge, attitudes and behaviour regarding health checks, whose contents this article has not cited, so this article carries no Hong Kong prevalence or frequency figure.
2. Hong Kong's false positive rate, follow-up testing rate and proportion of overdiagnosis. Every quantified figure here on false positives, follow-up testing and overdiagnosis is United States or international data. Not one is a Hong Kong figure, and none can be converted into a Hong Kong figure by population.
3. A recommended interval for "how often to have a body check" (that is, a package covering several organ systems). No source has supplied one, and this article will not derive one of its own. ⚠ This item must not be misread as "the government has published no intervals" — it has published item-by-item intervals; see the Live Well Plan section above. What is missing is an interval in the unit of a package.
4. The package prices of the eighteen providers, and an item-by-item comparison of their packages. No per-provider source a reader could check for themselves was obtained for any of those price figures, so the whole set (original prices, promotional prices, upgrade surcharges and cross-provider price ranges) is not reproduced here; for prices, rely on what each provider's own website carries on the day. Coverage was also uneven — one provider's catalogue page cannot be paged through, and another has readable item lists for only 2 of some 100 products — so any count of how many packages each provider has is incomplete, and this article offers no item-by-item comparison table either. Likewise this article offers no cross-provider price range of the kind "18 providers, 91 packages, HK$980–26,800": some of those providers in fact publish no general body check package, and others publish no prices on their own website, so the range does not hold up in the first place.
5. The full contents of the Consumer Council's body check surveys over the years. This article cites only the two press releases of 15 May 2023 and 14 July 2016, together with the plan count and the range of item counts recorded in CHOICE issue 304 (2002.02). No other issue is cited — in particular issue 443 (2013.09), which has no public content beyond its title, and to which this article attributes no finding.
6. Whether the Hong Kong government has a position on commercial body check packages as such. All this article can say is that none was found among the documents listed one by one above. The Hong Kong Medical Association (hkma.org / thkma.org) and the Department of Health's Central Health Education Unit (cheu.gov.hk) are outside the scope of that list, and this article makes no statement about them.
7. The fees and follow-up intervals of the Elderly Health Centres. No page-by-page source was available to cite, so no statement is made. ⚠ As for the Woman Health Service's successor arrangement, the Well Women Station, it does publish fees: its "Service Fees" page (self-noted last updated 6 July 2026) sets out basic service co-payments per attendance of $80 for the dedicated nurse clinic, $150 for medical assessment and consultation, $150 for cervical cancer screening (cervical cytology) and $250 for breast cancer screening (2D mammography), with value-added services charged item by item. That page publishes no follow-up interval, and this article makes no statement about intervals.
8. Whether any given body check provider accepts Elderly Health Care Vouchers. This article states only the scope of services listed on the voucher scheme's frequently asked questions page, and that the Chronic Disease Co-Care Scheme's official page states that vouchers apply. Whether any particular provider accepts them, and on what additional conditions, is not stated here.
9. The rule on the age to begin screening for high-risk breast cancer. The Chinese and English versions of that rule differ on the definition of "the youngest affected relative", and it is a rule that needs clinical assessment before it can be used; it is not reproduced here — see our article on breast cancer screening.
10. False positive data comparing annual with biennial mammography. That study was followed by an erratum whose contents this article has not obtained, so that set of figures is not cited.
11. Effectiveness figures for the screenings Hong Kong recommends (cervical, colorectal and breast cancer). This article cites no mortality or incidence outcome for any of them, so the harms figures given here cannot be used to infer whether to have them or not; the evidence of effectiveness for each of the three is in our dedicated articles.
12. The detail in appendix H of the Medical Council's code about which media a "range of consultation fees" may be published in. Whether that form's column headings can be read accurately out of the document is itself unsettled, so no statement is made.
13. The individual trials included in the Cochrane review, the contents of its GRADE tables, or its discussion section. The full text of that review could not be obtained, and this article cites only its abstract and plain language summary.
14. The children's Live Well Plan chart. This article cites only the men's and women's charts, and none of the content of the children's chart.

#Sources

• The Live Well Plan, men's chart (age bands and intervals for blood pressure, diabetes, blood lipids, body weight, oral health, colorectal cancer, prostate cancer and vaccination; the high-risk factors column): Health Bureau, Life Course Preventive Care Plan – Men, https://www.healthbureau.gov.hk/phcc/rfs/src/pdfviewer/web/pdf/lcpc/en/HP-HealthPlan-Men.pdf (foot self-noted Health Bureau (01/2026); retrieved 3 August 2026)
• The Live Well Plan, women's chart (adding cervical cancer, breast cancer and osteoporosis): Health Bureau, Life Course Preventive Care Plan – Women, https://www.healthbureau.gov.hk/phcc/rfs/src/pdfviewer/web/pdf/lcpc/en/HP-HealthPlan-Women.pdf (foot self-noted Health Bureau (01/2026); retrieved 3 August 2026)
• The chart's target population, "general asymptomatic (low risk) population", its four uses (including "patient education tool") and the "not meant to be exhaustive" sentence: Hong Kong Reference Framework for Life Course Preventive Care in Primary Healthcare, Chapter 5, https://www.healthbureau.gov.hk/phcc/rfs/src/pdfviewer/web/pdf/lcpc/en/14_en_LCPC.pdf (cover self-noted First Edition 2023 / First published: 2023, 31 pages in all; retrieved 3 August 2026)
• The basis for the three Live Well Plan charts being 「(只備英文版)」: the Chinese interface of the Health Bureau's primary healthcare Reference Framework site, https://www.healthbureau.gov.hk/phcc/main/frameworks.html (「健康人生計劃 - 兒童」, 「健康人生計劃 - 男士」 and 「健康人生計劃 - 女士」 each marked 「(只備英文版)」; retrieved 3 August 2026)
• The expert working group's summary of recommendations (the "not recommended" list of table one, the "recommended" list and intervals of table two, the items of the "higher risk" columns, the breast cancer risk factor footnote and the "important note" sentence): Centre for Health Protection of the Department of Health, Summary of Cancer Screening Recommendations of the Cancer Expert Working Group on Cancer Prevention and Screening, Chinese version, https://www.chp.gov.hk/files/pdf/12_summary_tables_on_extracted_cewg_recommendations_all_11_cancer_sites_chi.pdf ; English version https://www.chp.gov.hk/files/pdf/12_summary_tables_on_extracted_cewg_recommendations_all_11_cancer_sites_eng.pdf . Document self-noted year 2026 (retrieved 3 August 2026)
• The basis for the eleven professional recommendations being English only (and hence for all Chinese quoted here coming from the bilingual summary table): Centre for Health Protection, "Cancer Expert Working Group on Cancer Prevention and Screening" page, https://www.chp.gov.hk/tc/static/100854.html (retrieved 2 August 2026)
• 「所有篩查測試都有其局限性，也不是百分百準確。」, 「任何人士如出現懷疑患癌的症狀或身體變化，應盡快約見醫生作適當診斷和接受治療。」 and the definition of the purpose of screening: Centre for Health Protection Non-communicable Disease Branch, Cancer Prevention and Screening (Cancer Prevention Series, part one), Chinese version, https://www.chp.gov.hk/files/pdf/1_cancer_prevention_and_screening_chi.pdf , leaflet self-dated 「二零二五年三月」 (retrieved 3 August 2026)
• 「醫生會按個別人士的年齡、性別、健康狀況和家庭健康背景等而建議所需要檢查的項目。」, 「要聽取報告，並要求醫生給予你建議如何跟進問題和下次檢查的時間。」 and that page carrying no interval: Centre for Health Protection, "Men's body check — an introduction to men's health checks", https://www.chp.gov.hk/tc/static/80002.html (English version https://www.chp.gov.hk/en/static/80002.html , page title Men's Health Checks - Introduction to Health Checks) (retrieved 3 August 2026)
• Blood pressure "at least once every two years", the intervals to the next check on the optimal, normal and high normal rows, and notes 1, 2 and 3 below the table: Hong Kong Reference Framework for Hypertension Care for Adults in Primary Care Settings, Chinese version, Chapter 7, https://www.healthbureau.gov.hk/phcc/rfs/src/pdfviewer/web/pdf/hypertensioncareforadults/tc/coredocument/10_tc_hypertension_care_chapter7.pdf (retrieved 3 August 2026)
• That document's self-noted version year 「2021年修訂版／首次出版年份：2010／最後更新日期：2021」: the cover of the full Chinese document, https://www.healthbureau.gov.hk/phcc/rfs/src/pdfviewer/web/pdf/hypertensioncareforadults/tc/coredocument/15_tc_hypertension_care.pdf ; the cover of the full English document (Revised Edition 2021 / First published: 2010 / Last review date: 2021) https://www.healthbureau.gov.hk/phcc/rfs/src/pdfviewer/web/pdf/hypertensioncareforadults/en/13_en_RF_HT_full.pdf (retrieved 3 August 2026)
• The eligibility criteria and screening stage contents of the Chronic Disease Co-Care Scheme and the Hepatitis B Co-Care Scheme: Primary Healthcare Commission, "Eligibility" https://www.primaryhealthcare.gov.hk/cdcc/tc/gp/join_cdcc_enrol_now.html and "Introduction" https://www.primaryhealthcare.gov.hk/cdcc/tc/gp/introduction.html (the pages carry no date; retrieved 3 August 2026)
• All the co-payments for the screening and treatment stages, services outside the scope of the scheme, the two-way referral charges, and vouchers applying while fee waivers do not: Primary Healthcare Commission, "Subsidy and Co-payment" https://www.primaryhealthcare.gov.hk/cdcc/tc/gp/join_cdcc_co_payment.html (the page carries no date; retrieved 3 August 2026)
• The scheme being regularised from the pilot and renamed (13 March 2026): government press release https://www.info.gov.hk/gia/general/202603/13/P2026031300531.htm (retrieved 2 August 2026)
• Blood lipid testing added from 28 March 2025: government press release (20 March 2025) https://www.info.gov.hk/gia/general/202503/20/P2025032000216.htm (retrieved 2 August 2026)
• The definition of a general health check, the 17 trials and 251,891 people, the three mortality results, the authors' conclusion, the two explanations the authors themselves offer for "why no effect can be seen", the search cut-off, and the divergences between the English and Chinese versions: Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev 2019, Issue 1, Art. No.: CD009009 (DOI 10.1002/14651858.CD009009.pub3; PMID 30699470). English record page https://www.cochrane.org/evidence/CD009009_general-health-checks-reducing-illness-and-mortality (self-noted Published 30 January 2019); traditional-Chinese translation page https://www.cochrane.org/zh-hant/evidence/CD009009_general-health-checks-reducing-illness-and-mortality (retrieved 2 August 2026)
• The seven recommended questions on commercial screening, the two opening sentences of section 1 ("Good screening does more good than harm."), the list of harms of screening, the complete three-item list under section 5's "Drawbacks of commercially motivated screening include:", "screening does not provide a diagnosis", "Screening is not for people who have symptoms.", and "a test is not a programme": UK National Screening Committee, NHS and commercial health screening tests: important considerations, GOV.UK, https://www.gov.uk/government/publications/uk-nsc-commercial-screening-test-considerations/nhs-and-commercial-health-screening-tests-important-considerations (page self-noted Published 21 November 2023; Open Government Licence v3.0; retrieved 3 August 2026)
• The NHS Health Check's target group, exclusions and five-year interval: NHS, NHS Health Check, https://www.nhs.uk/tests-and-treatments/nhs-health-check/ (page self-noted Page last reviewed: 14 August 2023; retrieved 2 August 2026)
• "A normal result does not mean you will never develop the condition" and the explanations of false positives and false negatives: NHS, NHS screening, https://www.nhs.uk/tests-and-treatments/nhs-screening/ (page self-noted Page last reviewed: 30 July 2024; retrieved 2 August 2026)
• The definitions of sensitivity, specificity and positive predictive value, positive predictive value falling with prevalence, the three requirements for bundling (item-by-item validation, each item part of a care pathway, and meeting the requirements of the green cells of table 1), each test being assessed separately on its own merits, and the definition of overdiagnosis: WHO Regional Office for Europe. Screening programmes: a short guide. 2020, https://iris.who.int/items/ba910aa7-3c5a-4cf4-97d8-b128ac712881 (retrieved 1 August 2026)
• "Only 36% have all 20 results normal", the 95% reference range convention, the "the more abnormal the result…" sentence, the passage on the 68% serum insulin reference range, and the 82% and 98% under 99% and 99.9% reference ranges: Phillips P. Pitfalls in interpreting laboratory results. Aust Prescr 2009;32:43-6, https://australianprescriber.tg.org.au/articles/pitfalls-in-interpreting-laboratory-results.html (page self-dated 1 April 2009; DOI 10.18773/austprescr.2009.022; retrieved 3 August 2026)
• The cumulative risks of a false positive and of an invasive diagnostic procedure after 14 tests (men 60.4% / 28.5%, women 48.8% / 22.1%): Croswell JM, et al. Cumulative incidence of false-positive results in repeated, multimodal cancer screening. Ann Fam Med 2009;7(3):212-22 (PMID 19433838; DOI 10.1370/afm.942)
• 86% of 1,192 people having a finding on whole-body computed tomography, 37% advised to have further investigation, and the conclusion "most findings were benign by description and required no further evaluation": Furtado CD, et al. Whole-body CT screening: spectrum of findings and recommendations in 1192 patients. Radiology 2005;237(2):385-94 (PMID 16170016; DOI 10.1148/radiol.2372041741)
• The pooled cancer detection rate of 1.57% among 9,024 asymptomatic people having whole-body magnetic resonance imaging, and the authors' own statement of the risk of bias: Martins da Fonseca J, et al. Whole-body MRI for opportunistic cancer detection in asymptomatic individuals: a systematic review and meta-analysis. Eur Radiol 2026;36(3):1813-1823 (PMID 40884613; DOI 10.1007/s00330-025-11976-5)
• The 94% / 18% / 4% / 1.5% among 132 asymptomatic Hong Kong doctors having whole-body magnetic resonance imaging: Lo GG, et al. Magnetic resonance whole body imaging at 3 Tesla: feasibility and findings in a cohort of asymptomatic medical doctors. Hong Kong Med J 2008;14:90-6, https://www.hkmj.org/abstracts/v14n2/90.htm (retrieved 2 August 2026)
• The psychosocial effects three years after a false positive (12 measures, 4 reaching P<0.01): Brodersen J, Siersma VD. Long-term psychosocial consequences of false-positive screening mammography. Ann Fam Med 2013;11(2):106-15 (PMID 23508596; DOI 10.1370/afm.1466)
• "No scientific evidence that whole-body scanning of asymptomatic people provides more benefit than harm" and "an abnormal finding may not be serious and a normal finding may be inaccurate": U.S. FDA, Full-Body CT Scans - What You Need to Know, https://www.fda.gov/radiation-emitting-products/medical-x-ray-imaging/full-body-ct-scans-what-you-need-know (page self-noted Content current as of: 12/05/2017; retrieved 2 August 2026)
• 10 millisieverts and one chance in two thousand, 400 rising to 400-plus-one in two thousand, the dose table and its uncertainty: U.S. FDA, What are the Radiation Risks from CT?, https://www.fda.gov/radiation-emitting-products/medical-x-ray-imaging/what-are-radiation-risks-ct (the dose table reproduced from McCollough CH, et al. Mayo Clin Proc 2015;90(10):1380-92; retrieved 2 August 2026)
• The annual physical examination of 1922, its withdrawal in 1983, the scoring of the packages of eleven Hong Kong private hospitals in 2000, and 「沒有任何權威機構發出正式指引」 (a statement of December 2000): Dickinson JA, Chee S. Preventive services advertised to the public by private hospitals in Hong Kong. Hong Kong Med J 2000;6:415-22, https://www.hkmj.org/abstracts/v6n4/415.htm (full text PDF https://www.hkmj.org/system/files/hkm0012p415.pdf ; retrieved 2 August 2026)
• The sampling frame of the 33 plans, fees from $820 to $8,310 differing by more than 9 times (comparing the lower fee), more than 5 in ten plans (18) displaying two fees, more than 9 in ten private provider plans (15) offering fewer than half of the basic items and 8 of those offering only 1 assessment item, more than 9 in ten private hospital plans (16) containing half or more, "liver function" split into 13 items and "blood cell analysis (complete blood picture)" into 14, about 3 in ten plans (10) carried out by non-doctors only, 「撇除沒有提供相關資料的2個計劃，有5個計劃沒有包括由醫生講解報告」, the 「一般人士應最少每年進行1次高血壓檢查」 passage, the Council's named citation of the Cancer Expert Working Group, and its two closing sentences: Consumer Council press release, https://www.consumer.org.hk/tc/press-release/p-559-body-check-plans (page self-dated 2023.05.15; retrieved 3 August 2026). ⚠ The CHOICE magazine article page is in Chinese only; the press release itself is bilingual
• 「最少有12間私家醫院提供62個計劃⋯⋯檢查項目可由4個至超過50個」: Consumer Council CHOICE magazine issue 304 (page self-dated 2002.02)
• 「根據基層醫療署推出的《香港高血壓參考概覽 - 成年高血壓患者在基層醫療的護理》，18歲或以上的成年人應每兩年最少量度血壓一次。」 and the sentence following about individuals needing more frequent monitoring: Centre for Health Protection press release on World Hypertension Day, https://www.info.gov.hk/gia/general/202605/17/P2026051700268.htm (press release dated 17 May 2026; retrieved 3 August 2026)
• The scope of services the vouchers cover, 「醫療券可用於預防性及治療性的服務，但不可用來純粹購買物品⋯⋯」 (item 7); and 「獎賞只可用於預防疾病或管理健康等的特定基層醫療用途，包括：⋯⋯西醫：健康評估、驗身、篩檢⋯⋯」 (item 41, the Elderly Health Care Voucher Reward Pilot Scheme) with the conditions for granting that reward (item 39): Elderly Health Care Voucher Scheme frequently asked questions, https://www.hcv.gov.hk/tc/faqs/faqs_vr.html (retrieved 3 August 2026)
• The Well Women Station's basic service co-payments (dedicated nurse clinic $80, medical assessment and consultation $150, cervical cancer screening $150, breast cancer screening $250) and that page carrying no follow-up interval: Well Women Station, "Service Fees", https://www.wws.org.hk/page/service-charge (page self-noted last updated 6 July 2026; retrieved 3 August 2026)
• Packages being largely of the "unconditional" kind, false positives on resting and exercise electrocardiography, false negatives on chest X-ray, tumour markers not being suitable as screening on their own, and reports being interpreted by a doctor whether normal or not: Consumer Council press release, https://www.consumer.org.hk/ws_chi/news/press/477/checkup-packages.html (English version https://www.consumer.org.hk/ws_en/news/press/477/checkup-packages.html ; page self-dated 2016.07.14; retrieved 2 August 2026)
• The price transparency provisions of the Private Healthcare Facilities Ordinance (Chapter 633) not being in operation: Consumer Council press release on its study report on price transparency in healthcare, https://www.consumer.org.hk/tc/press-release/p-private-healthcare-services-study-report (English version https://www.consumer.org.hk/en/press-release/p-private-healthcare-services-study-report ; page self-dated 2025-03-06; retrieved 1 August 2026)
• A health check establishing a doctor-patient relationship (section 1.2.1), the prohibition on touting (section 5.2.5), and the code having no provision aimed at commercial body check packages: Medical Council of Hong Kong, Code of Professional Conduct for the Guidance of Registered Medical Practitioners (revised October 2022), https://www.mchk.org.hk/tc_chi/code/files/Code_of_Professional_Conduct_(Chinese_Version)_2022.pdf (English version https://www.mchk.org.hk/english/code/files/Code_of_Professional_Conduct_(English_Version)_(Revised_in_October_2022).pdf ; retrieved 2 August 2026)
• The Hong Kong Academy of Medicine's published list of policy statements and research reports (8 in all, all on training, education or diversity and inclusion): https://www.hkam.org.hk/en/policy-statements-corporate-and-medical-publications (retrieved 2 August 2026)
• "rational screening intervals, rather than as ad hoc check-up packages": Hui An-tung, editorial, Hong Kong Practitioner, April 2005 (Vol 27 No 4), https://www.hkcfp.org.hk/Upload/HK_Practitioner/2005/hkp2005vol27apr/editorial.html (retrieved 2 August 2026)
• "The real benefit of screening is early treatment, not just early detection.": Chan Siu-bun, Wong Wai-bun and Tang Kuen-yan, Quaternary prevention for primary care practice, Parts 1 & 2, Hong Kong Practitioner, December 2024 (Vol 46 No 4) and March 2025 (Vol 47 No 1) (retrieved 2 August 2026)
• 「體檢是要在身體健康的情況下定期進行」 and thyroid ultrasound and overdiagnosis: Tsuen Wan Adventist Hospital, 〈了解體檢流程 檢查項目勿過多免過度診斷〉, https://www.twah.org.hk/tc/conditions-and-treatments/gain-a-clear-understanding-of-the-medical-check-up-process-avoid-unnecessary-tests-to-reduce-the-risk-of-overdiagnosis-chinese-version-only (the page carries no author or date; retrieved 2 August 2026)
• 「儘管檢查結果表面上屬正常，還是有可能有某些隱藏的疾病在稍後時間才會顯現」: Medtimes terms of service page, https://www.medtimes.com.hk/terms (retrieved 2 August 2026)
• 「很多人以為驗身套餐中的體檢項目越多越好，其實這想法是不正確的」: the frequently asked questions on Quality HealthCare's own "Health Check" page (retrieved 2 August 2026)
• The "Health Check and Preventive Medicine" page listing no package prices: UMP Healthcare, https://www.ump.com.hk/server.php?id=9&lang_id=1 (retrieved 2 August 2026)
• Whether each provider's price page self-notes an effective or updated date, how promotions are labelled, differences between Chinese and English pages, differences in package contents and footnotes: each provider's own website and own published price documents (Hong Kong Sanatorium & Hospital, Blue Care, Matilda International Hospital, Hong Kong Baptist Hospital Day Medical Centre, Gleneagles Hospital Hong Kong, Union Hospital, Tsuen Wan Adventist Hospital, Hong Kong Adventist Hospital – Stubbs Road, re:HEALTH, Mobile Medical, Medtimes, Trinity Medical Centre, Quality HealthCare, Zenith Medical Centre, St Paul's Hospital, CUHK Medical Centre, Humansa, UMP), retrieved 2 August 2026. ⚠ This article does not reproduce those providers' price figures; see item 4 of "What this article does not state"
• The full accounts of cervical, breast and colorectal cancer screening: see our articles on cervical cancer screening, breast cancer screening, colorectal cancer screening, and colonoscopy and gastroscopy
• Why a laboratory report is read the way it is, and where reference ranges come from: see our article on laboratory and imaging reports

This article was compiled by the editorial team from official and academic sources, with every clinical statement attributed; it is health information, not medical advice. Whether you need any examination, and how often, is for a doctor to decide on your individual circumstances.